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Abstract
Parkinson's disease (PD) is a neurodegenerative disease, which is characterized by progressive 
death of dopaminergic neurons in the substantia nigra pars compacta. Although mitochondrial 
dysfunction and oxidative stress are linked to PD pathogenesis, its etiology and pathology remain 
to be elucidated. Metabolomics investigates metabolite changes in biofluids, cell lysates, tissues 
and tumors in order to correlate these metabolomic changes to a disease state. Thus, the 
application of metabolomics to investigate PD provides a systematic approach to understand the 
pathology of PD, to identify disease biomarkers, and to complement genomics, transcriptomics 
and proteomics studies. This review will examine current research into PD mechanisms with a 
focus on mitochondrial dysfunction and oxidative stress. Neurotoxin-based PD animal models and 
the rationale for metabolomics studies in PD will also be discussed. The review will also explore 
the potential of NMR metabolomics to address important issues related to PD treatment and 
diagnosis.
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1. Introduction
PD is the second most common neurodegenerative disorder behind Alzheimer's disease 
[1-3]. In 2005, 4.1 to 4.6 million people were estimated to have PD worldwide, with a high 
prevalence of PD in the United States [4]. Aging is one of the strongest risk factors 
associated with PD (Figure 1a) [5, 6]. Correspondingly, as the world population continues to 
age, the number of PD cases is predicted to double by 2030, imposing an increasing burden 
on the healthcare systems in many countries. In the U.S.A. alone, the annual economic cost 
of Parkinson's disease is estimated at $10.8 billion [7]. As a result, maintenance of 
functional independence at advanced ages has become a critical public health priority [8].
PD patients suffer from a range of movement disorders (bradykinesia, postural instability, 
rigidity, tremors) collectively known as Parkinsonism. Parkinsonism is mainly caused by the 
degeneration of dopaminergic neurons (DAergic) in the substantia nigra pars compacta 
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(SNpc) and the resulting depletion in dopamine. However, a large proportion of PD patients 
also suffer from other non-motor symptoms (anosmia, autonomic dysfunction, 
hallucinations, sleep disorders) [9]; along with neuronal loss in many other brain regions. 
This can occur before or after the loss of DAergic neurons [10, 11]. Currently, the diagnosis 
of PD depends primarily on the observation of motor symptoms in a clinical setting. 
Unfortunately, the rate of misdiagnosis of PD may be upwards of 50% [12]. This is due to 
the absence of symptoms in the early stages of the disease, and a variation of symptoms 
among individual patients [13]. There is also no cure for PD. Current treatments focus on 
addressing the symptoms and reducing the progression of the disease [14-17]. The standard 
treatment for PD consists of replacing dopamine with L-DOPA (Figure 2), a dopamine 
precursor [18]. Unfortunately, the effectiveness of L-DOPA declines as the disease 
progresses; leading to serious side-effects.
Despite decades of investigation, the PD mechanism of pathogenesis is still unknown and 
dopamine depletion may be merely a consequence of PD. Several studies have shown that 
proteinaceous inclusions (Lewy bodies and Lewy neuritis) are localized in different areas of 
a PD brain (Figure 1b) even before dopamine loss and Parkinsonism symptoms occur 
[19-21]. These proteinaceous inclusions are composed of lipids and several proteins, such as 
α-synuclein (PARK1) [22]. Correspondingly, current hypotheses for PD pathogenesis are 
based on protein misfolding and aggregation [23], mitochondrial dysfunction [24], or 
oxidative stress [25]. Initially, these pathogenesis routes were thought to work 
independently, but recent data strongly suggests they interact together to deplete dopamine 
[26].
In this review, we will briefly summarize current models and supportive evidence for the 
molecular mechanisms of PD, with a specific focus on mitochondrial dysfunction and 
oxidative stress. We will provide a background and rationale for the utility of metabolomics 
to investigate PD with a particular emphasis on the application of NMR-based 
metabolomics. Metabolomics has a tremendous potential to provide valuable insights into 
the etiopathogenesis of PD, to discover novel molecular targets for the treatment of PD, and 
to identify reliable and sensitive PD biomarkers. Biomarkers may play an important role in 
the early diagnosis of PD, in monitoring the progression of PD, and in determining the 
efficacy of therapeutic intervention. Metabolomics methodology and its application to PD 
will also be briefly described. The proper choice and handling of cellular and animal models 
are critical to a successful metabolomics study. Thus, the most commonly used animal PD 
models and their application to metabolomics will also be summarized.
2. Discussion
2.1. Risk Factors of PD
Studies on the etiology of PD have revealed multiple factors. In addition to aging, PD has 
been shown to have a genetic association [27], and a correlation with head trauma [28] and 
exposure to pesticides and herbicides (Figure 2) [29]. Specifically, PD has been associated 
with exposure to paraquat, carbamates, and organochlorines [30, 31]. Not surprisingly, the 
Midwest of the USA have a high prevalence of PD with Nebraska having the highest 
number of PD patients per capita [6]. A byproduct of a synthetic opioid (MPPP, 1-methyl-4-
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phenyl-4-propionoxypiperidine), 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is 
chemically similar to paraquat and also results in PD-like motor symptoms and further 
supports an environmental cause of PD.
Additionally, there are genetic links that associate PD with pesticides and herbicides [32]. In 
fact, a recent study suggests that an environmental-genetic interaction plays a more 
important role in PD than do either genetic or environmental factors alone [33]. A genetic 
analysis of an Italian family [34] and a western Nebraska family [35] identified an 
association between the α-synuclein (PARK1) and leucine-rich repeat kinase 2 (LRRK2/
PARK8) genes and the development of both familial and sporadic PD. Similar genetic 
studies have identified mutations in the protein Parkin (PARK2) as the most common 
indicator of familial PD [36]. Other genetic studies have identified a correlation with PD for 
mutations in lysosomal protein glucocerebrosidase (GBA) [37], PTEN-induced putative 
kinase 1 (PINK1/PARK6) [38], and the DJ-1 protein (PARK7) [39]. The majority of PD 
cases are sporadic [1], where α-synuclein (PARK1) and leucine-rich repeat kinase 2 
(LRRK2/PARK8) are associated with autosomal-dominant forms of PD and Parkin 
(PARK2), PTEN-induced putative kinase 1 (PINK1/PARK6), DJ-1 protein (PARK7) are 
associated with autosomal recessive forms of PD [40].
Mutations in leucine-rich repeat kinase 2 (LRRK2/PARK8) usually results in mid-to-late 
onset PD with a slow disease progression through an unknown mechanism. 
Correspondingly, the neuropathology is generally inconsistent. Conversely, mutations in α-
synuclein (PARK1) often lead to early-onset PD with a rapid disease progression and the 
presence of Lewy bodies and α-synuclein (PARK1) fibrils. The mutation in GBA possibly 
leads to an increase in α-synuclein (PARK1) aggregation [41]. Parkin (PARK2) mutations 
results in juvenile and very early-onset PD that progresses very slowly. It causes neuronal 
loss and gliosis in the substantia nigra, but commonly lacks Lewy bodies. Indistinguishable 
clinical outcomes occur with mutations in PINK1 (PARK6) and DJ-1/PARK7. Importantly, 
mutations in Parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7) and exposure to pesticides 
and herbicides appear to alter redox balance leading to neuronal death [42]. Parkin (PARK2) 
is involved in protein ubiquitination and interacts with synphilin-1, which interacts with α-
synuclein (PARK1). DJ-1/PARK7 has an unknown function, but has been associated with a 
protective role related to oxidative stress. PINK1 (PARK6) is upstream of Parkin (PARK2) 
in a pathway associated with eliminating damaged mitochondria [38, 43, 44]. The 
mitochondria are a major provider of cellular energy and also play a key role in cell death 
(apoptosis) [45, 46]. The brain has the highest energy requirement of all organs and, 
correspondingly, neuronal mitochondria are subjected to high levels of oxidative stress and 
potential damage that may lead to cell death. As a result, mitochondrial quality control 
pathways have evolved to maintain molecular function or eliminate a dysfunctional 
organelle, where the impairment of these processes is associated with PD [43, 44].
2.2. Mitochondrial dysfunction and oxidative stress in PD
Oxidative stress is caused by a cumulative production of free radicals, typically known as 
reactive oxygen species (ROS) and reactive nitrogen species (RNS). Elevated level of ROS 
may result in a significant damage to DNA, proteins and lipids [47]. Brain tissues are more 
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susceptible to oxidative stress due to (i) a low concentration of antioxidant enzymes and a 
low ability to maintain energy homeostasis [48], (ii) a high consumption of the total 
available oxygen [49, 50], (iii) a high percentage of polyunsaturated fatty acids [51], and (iv) 
the increased presence of redox metals (iron, copper and zinc) in an aging brain [52]. 
Among many sources of free radical production, metal-catalyzed reactions and 
mitochondria-catalyzed electron transport reactions are two potential sources of PD-related 
ROS [53]. It is thought that 95-98% of ROS generated during aerobic metabolism are from 
mitochondrial activity [54]. As a result, mitochondria contain an extensive antioxidant 
defense system, where a damaged or dysfunctional mitochondrion leads to an increase in 
ROS [55].
Dopaminergic neurons in the substantia nigra pars compacta region are also very prone to 
oxidative damage because of (i) higher iron and copper levels in this region of the brain, 
higher activity of monoamine oxidase, and aberrant oxidation of dopamine that all lead to a 
higher intrinsic ROS, (ii) higher sensitivity to ROS signaling that induces apoptosis, (iii) 
lower mitochondrial mass, lower ATP levels and dysfunctional mitochondria, (iv) readily 
activated mitochondrial permeability transition (MPT) pore by dopamine metabolite that 
leads to cell death, (v) deficient DNA damage repair, (vi) glial dysfunction, (vii) calcium 
dysregulation and glutamate hyperactivity, and (viii) the large size of the neurons and higher 
demand for energy [56, 57].
Mitochondria were implicated in PD by two cases involving young drug users taking illicit 
narcotics contaminated with MPTP [58]. Later studies implicated the MPP+ (1-methyl-4-
phenylpyridinium) metabolite of MPTP (Figure 2) as the cause of Parkinsonism in these 
designer-drug abusers. MPP+ inhibits complex I of the mitochondrial electron-transport 
chain [59]. This model has been supported by animal studies, in which the chronic infusion 
of rotenone [60] (another complex-I inhibitor) or MPTP [61] results in a clinical 
parkinsonian phenotype, and pathological nigrostriatal dopamine degeneration with 
cytoplasmic inclusions immunoreactive for α-synuclein (PARK1) and ubiquitin [62]. 
Oxidative stress is the probable mechanism of toxicity for complex-I inhibitors [63]. 
Complex-I inhibition and oxidative stress were shown to be relevant to naturally occurring 
PD when complex-I deficiency and glutathione depletion were found in the substantia nigra 
of patients with idiopathic PD, and in patients with pre-symptomatic PD [64]. In addition, 
many of the genes associated with PD also have a functional role in the mitochondria. Choi 
et al. argues that mitochondrial complex I inhibition is not required for dopaminergic neuron 
death induced by retenone, MPP+, or paraquat. A mouse strain lacking functional Ndufs4, 
which abolishes complex I activity in midbrain mesencephalic neurons cultured from 
embryonic day 14 mice, showed no effect on the survival of dopaminergic neurons in 
culture [65].
2.3. PD animal models
Animal models are essential tools to study etiology, pathogenesis, and the molecular 
mechanisms of PD in vivo. Over the past decades, various animal models have been 
developed for PD research [66-68]. These animal models can be generally categorized into 
toxin-based models and genetic models.
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Toxin-based models typically rely on dosing animals with MPTP, 6-hydroxydopamine (6-
OHDA), rotenone or paraquat. Given the well-known cases of PD-like motor symptoms 
induced by MPTP associated drugs, MPTP has been widely used as a model for PD. 
Administration of MPTP mimics human PD in many aspects, such as selective lesion of 
substrantia nigra dopaminergic neurons and the presence of α-synuclein (PARK1) 
aggregates. Unlike PD, the MPTP animal model is an acute, non-progressive disease. The 
neuron toxin 6-OHDA has the longest history of use as a PD model and has been commonly 
used to degenerate central catecholaminergic projections, including the nigrostriatal system 
[69, 70]. Although dopamine depletion, nigral dopamine cell loss, and neurobehavioral 
deficits have been observed with the 6-OHDA model, it does not mimic all of the clinical 
features of PD. The 6-OHDA animal model does not form Lewy bodies, and it does not 
affect other PD involved brain regions, such as olfactory structures, lower brain stem areas, 
or locus coeruleus [71]. The rotenone animal model is the first to link an environmental 
toxin to PD development [72, 73]. Rotenone administration produces hallmark traits of PD, 
such as nigrostriatal dopamine neurons damage, α-synuclein (PARK1) aggregation, Lewy-
like body formation, oxidative stress, and gastrointestinal problems [74].
A number of genetic animal models have been created by mutating PD associated genes, 
such as, α-synuclein (PARK1) [75, 76], LRRK2 (PARK8) [77, 78], PINK1 (PARK6), 
Parkin (PARK2) [79, 80], DJ-1 (PARK7) [81] and ubiquitin C-terminal hydrolase-L1 
(PARK5) [82]. Interestingly, these genetic models do not present PD related neuronal 
degeneration, but they provide systems for investigating PD pathogenesis, for evaluating 
potential therapeutic targets, and to assist in the drug discovery process.
2.4. The rationale for PD metabolomics studies
Metabolomics refers to the study of the metabolome, the collection of small molecules, such 
as amino acids, carbohydrates and lipids, present in cells, tissues, organs, or biological fluids 
[83-89]. Metabolomics combines analytical techniques (IR, NMR, MS, etc.) [85, 90, 91] 
with multivariate statistical methods [92] to analyze metabolite concentration changes in a 
high throughput manner. Metabolomics is a relatively new omics discipline that is 
complementary to genomics and proteomics, and an important addition to systems biology 
[86, 93-95]. The identities, concentrations, and fluxes of the metabolites within a 
metabolome are a direct consequence of protein activity, and, importantly, change in 
response to the environment (disease state, drug treatment, nutrient availability, genetic 
modification, etc.). Thus, the metabolome reflects the state of a cell or biological system and 
can provide an overall picture of how the system responds to a specific perturbation. Thus, 
metabolomics is routinely used to define phenotypes [96-98]. Conversely, a change in the 
expression level of a gene or protein from a genomics or proteomics study is not necessarily 
correlated with a change in protein activity, or directly linked to a disease state. In addition 
to studying disease pathogenesis, metabolomics is used in drug discovery to identify 
chemical leads [99] and novel therapeutic targets [100]. Metabolomics is also a powerful 
tool for the identification of biomarkers for early disease detection, for monitoring disease 
progression, and the response to therapy [83]. Biomarkers have been identified from a 
variety of bodily fluids that include cerebrospinal fluid (CSF) by NMR imaging and GC-MS 
[101], feces by NMR [102], saliva by CE-MS [103], serum by NMR [104], and urine by 
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NMR [105]. Metabolomics has been applied to a wide-variety of human diseases including 
cardiovascular diseases [106], diabetes [107], and various types of cancer [108]. 
Metabolomics has also been successfully applied to investigate central nervous system 
disorders such as Alzheimer's Disease [109], Huntington's disease [110], motor neuron 
disease [111], and schizophrenia [112]. Paige et al. reported an alteration in several 
metabolites between depressed patients and controls by performing an MS-based 
metabolomics analysis of blood plasma samples [113]. Given that PD pathology may be 
closely related to protein misfolding and aggregation, mitochondrial dysfunction and 
oxidative stress, metabolomic changes would also be expected for PD.
PD is a complex and heterogeneous disease where metabolomics holds the promise of 
identifying specific disease-related networks to enhance our understanding of the multiple 
interrelated pathways of pathogenesis. This, in turn, may lead to the identification of novel 
therapeutic targets and the development of new treatments. Moreover, the application of 
metabolomics may result in the discovery of PD biomarkers for diagnosing the disease. 
Validated PD biomarkers would aid in the early detection of the disease and address the high 
misdiagnosis rate for PD [114, 115]. PD biomarkers would also allow for the accurate 
evaluation of disease progression, which would be invaluable in assessing the efficacy of a 
patient's treatment [116].
2.5. NMR-based metabolomics methodology
Due to the large size and diversity in the chemical and physical properties of the 
metabolome [117, 118], a range of analytical techniques have been applied to characterize 
metabolites present in a biological sample. Common analytical techniques used for 
metabolomics include NMR [85], GC-MS [119], LC-MS [120] and LC-electrochemistry 
array metabolomics platforms (LCECA) [121]. These analytical techniques have both 
advantages and limitations; and as a result are complementary to each other. Thus, it is 
common to integrate multiple techniques in a metabolomics study [122-124]. NMR 
spectroscopy has been used to investigate a wide range of diseases such as cancers 
[125-127], aging [128], heart disease [129], polycystic ovary syndrome [130, 131], and 
diabetes [132]. Correspondingly, NMR has some unique advantages that include: minimal 
sample handling, high reproducibility, easy quantitation, non-destructive, structural 
determination, and high throughput [87, 133-136]. Although we only discuss NMR-based 
methodologies in this review, there is a common work flow that is independent of the 
analytical method employed. This work flow is comprised of sample collection, sample 
preparation, data processing and analysis, and metabolite pathway identification (Figure 3). 
However, the experimental details for these processes (sample preparation, data analysis, 
etc.) still need to be optimized for the specific analytical technique utilized.
Various types of biological samples can be analyzed by NMR which includes cell extracts, 
tissue extracts, and numerous biofluids. Moreover, intact tissues can be analyzed by using 
high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS) after a 
simple sample preparation procedure [137]. For a typical PD in vitro study, intracellular 
metabolites are acquired by quenching and lysing neuron cells, followed by extracting the 
metabolome. Cerebrospinal fluid (CSF) is a preferred choice for a PD in vivo study. 
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However, there are associated risks with obtaining CSF from patients that diminishes its 
value as a routine diagnostic tool [138, 139]. Instead, easily accessible biofluids (plasma, 
serum, urine) provide a safer alternative. Procedures for preparing metabolomic samples 
from mammalian cell lines and biofluids have been extensively reviewed [88, 133, 
140-164].
The metabolome is a complex heterogeneous collection of compounds with a diversity of 
physiochemical properties, where specific metabolite stability and enzymatic turn-over rates 
are highly variable [161, 162]. It is essential that the extracted or collected metabolome 
reflects the true state of the system and is biologically relevant. In effect, changes to the 
metabolome should not be introduced by sample handling. Thus, a reliable sampling 
protocol is critical to a successful metabolomics study, where rapid sample collection and 
analysis are important [163]. For example, rapid quenching of cells with cold methanol 
avoids the more time consuming and physiological stressful trypsinization applied in 
conventional sampling methods [164]. Residual enzymatic activity or induction of stress 
response pathways (e.g. apoptosis) from trypsinization would alter the metabolome. Sample 
preparation is considerably simpler for biofluids. The sample is filtered or centrifuged; and 
then spiked with a deuterated phosphate buffer containing a preservative or anticoagulant 
[88, 89].
The application of NMR for the analysis of metabolomics samples has also been extensively 
reviewed [83-85, 87, 134, 165-170]. A typical one-dimensional (1D) 1H NMR spectrum can 
be acquired in a few minutes using an automated high throughput protocol [171]. The 
resulting 1D 1H NMR spectrum provides a global “fingerprint” or “snap-shot” of the 
metabolome for each sample. Thus, the 1D 1H NMR spectrum is routinely used to 
characterize a particular class (healthy or diseased, control or drug treated, etc.) and to 
identify the global features that distinguish between the classes or groups. This initial global 
analysis of the metabolome doesn't rely on identifying changes to individual metabolites (or 
assigning the highly complex NMR spectrum). Instead, multivariate statistical methods 
(principal component analysis, PCA; partial least squares, PLS; orthogonal projection to 
latent structures, OPLS) are applied to identify the spectral features that distinguish between 
the classes or groups [92, 172-175]. In general, the outcome of PCA, PLS, or OPLS is a 
scores plot, where each 1D 1H NMR spectrum is reduced to a single point in the plot (Figure 
4). Simply, the NMR spectrum consisting of a range of chemical shifts (ppm) and peak 
intensities is transformed into a multidimensional Cartesian space, where each axis (V1, V2, 
V3, … Vn) corresponds to a chemical shift and the value along each axis is the intensity of 
the NMR peak at that given chemical shift. If the NMR spectrum was collected with 32K 
data points there would be 32K axes. PCA then identifies a principal component vector 
 within this multidimensional space corresponding to the largest variation in the data 
set. A second vector  orthogonal to  is identified that corresponds to the next 
largest variation in the data set. Each successive vector describes a diminishing amount of 
the variability of the data set, where most of the variability is described by the first two or 
three principal components. The PC1 and PC2 scores (unitless values) are the individual fit 
of each NMR spectrum to  and , respectively, and are usually presented in a 2D 
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plot. The relative clustering of the NMR spectra in the scores plot identifies the relative 
similarity or differences between each spectrum, and correspondingly, their metabolomes. In 
essence, PCA, PLS, or OPLS is used to determine if a statistically significant difference in 
the metabolome has occurred as a result of the applied environmental stress (disease state, 
drug treatment, genetic modification, etc.). To be clear, PCA, PLS, and OPLS do not 
provide a direct analysis of the statistical significance of group separation in a scores plot. 
Instead, other utilities, such as a Mahalanobis distance metric and T2 and F distributions are 
required to return p values for quantitation of PCA, PLS, or OPLS group separations [176].
Multivariate statistical methods are classified into supervised (PLS, OPLS) and 
unsupervised (PCA) approaches. PCA [172, 173] is the most popular unsupervised 
algorithm routinely used in metabolomics. Importantly, PCA provides an unbiased view of 
the clustering patterns for all the conditions under investigation, and should be routinely 
employed to verify that a spectral difference actually exists. PCA directly analyzes the NMR 
spectra without any user intervention. If a true difference exists between the various classes, 
then all members within a class will cluster together and separate from the other classes in 
the resulting PCA scores plot. This occurs without PCA having any prior knowledge of the 
class membership for each NMR spectrum. In principal, PCA can actually be used to 
identify the class membership for each NMR spectrum. Thus, PCA can also be used as a 
quality control to identify outliers [177]. Of course, this assumes that the samples and 
spectra were not biased by experimental procedures or data processing.
PLS and OPLS are commonly used supervised methods, [174, 175]. The major difference 
between PCA and PLS/OPLS is that class membership is defined prior to PLS or OPLS. 
Thus, OPLS and PLS are inherently biased techniques since class designations are explicitly 
incorporated into the analysis. In effect, PLS/OPLS will only identify spectral differences 
that correlate with the manually defined class designations. This occurs regardless of the 
significance of these differences compared to other spectral features. As a result, an OPLS 
or PLS scores plot will always show a separation based on the manually defined class 
designation, even for completely random data [178]. Thus, OPLS and PLS can easily be 
misleading and requires validation of the model.
Cross validation and permutation testing [179] and CV-ANOVA [180] are routinely 
employed to validate OPLS and PLS models. For cross validation, the PLS/OPLS models 
are generated with a subset of the data, where the quality of the fit of the held-out data is 
measured against the model. The process is repeated numerous times, where different 
subsets of the data are held-out. The resulting quality assessment (Q2) statistic has no 
standard of comparison besides its theoretical maximum of 1 or an empirically acceptable 
value of ≥ 0.4 [179]. Unfortunately, a large Q2 value is still possible for an invalid model. 
The R2 values provide a measure of the fit of the data to the model, while it is not a measure 
of cross-validation an R2 ≫ Q2 indicates a possible over-fitting of the model. For 
permutation, the class designations are randomly changed and the quality of the model (Q2) 
is assessed and compared against the model with the correct classification. Again, the 
process is repeated numerous times where the correct classification is expected to yield the 
largest Q2 value. Also, a p value can be calculated based on the distribution of Q2 values for 
the incorrect class designations relative to the Q2 value for the correct model. Similarly, CV-
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ANOVA provides a p value for the PLS/OPLS model based on the cross-validated 
predictive residuals of a model as a basis for hypothesis testing.
Supervised analyses does provide valuable clues on biomarkers - the metabolites that 
experienced the largest change and primarily contribute to the class distinction in the PLS or 
OPLS scores plot. These potential biomarkers can then be targeted for further investigation. 
Potential biomarkers are typically identified from an S-plot [181] generated by the PLS or 
OPLS model (Figure 3). Basically, the extreme regions of the S-plot identify the spectral 
features (chemical shifts, metabolites) that significantly contribute to the class distinctions 
observed in the scores plot. A number of other data analysis methods are also used to 
analyze NMR metabolomics spectra [182], a few select examples include self-organizing 
map (SOM) [183, 184] support vector machines (SVM) [185, 186], and hierarchical 
clustering (HCA) [187].
The primary difference between PLS and OPLS is that OPLS attempts to maximize the 
separation between the classes along the X-axis with unrelated (orthogonal) variations along 
the Y-axis. As a result, OPLS minimizes within class variations. To be clear, any separation 
along the Y-axis in an OPLS scores plot is not correlated with the manually defined class 
designations. In other words, for OPLS a corresponding PLS scores plot is rotated to align 
the maximal separation between the classes along the X-axis.
Comparable to sample preparation, multivariate statistical methods are also very sensitive to 
the quality of the input data, where the results can be biased by data handling and processing 
protocols [178]. Basically, PCA, OPLS or PLS will highlight any spectral difference 
regardless of the source. Baseline distortions, incorrect phasing, chemical shift referencing 
errors, chemical shift and line shape perturbations, and irrelevant variations in spectral 
intensities due to instrument performance or sample preparations are all common NMR 
issues. NMR chemical shifts are very sensitive to subtle changes in temperature, pH, ionic 
strength, and instrument stability. Therefore, it is important to implement a uniform data 
pre-processing protocol that includes spectral alignment, binning, data normalization and 
data scaling [92]. The spectra can be aligned by using an internal standard like TMSP-d4 or 
computationally aligned using a variety of methods [188-193]. Importantly, an internal 
standard can only correct for a uniform deviation in chemical shifts that may arise between 
replicate samples. For example, chemical shifts generally change linearly with temperature, 
but a subtle variation in pH may result in large chemical shifts for some peaks, while others 
are essentially unchanged. Also, the direction of chemical shift change due to pH differences 
may vary between peaks. NMR spectra are also commonly binned to minimize minor 
variations in peak position and peak shape, and to filter out noise. The NMR spectrum is 
divided into “bins” having typical widths of 0.04 ppm, where the total peak intensity within 
each bin is integrated. “Intelligent” or “adaptive” binning uses variable bin sizes to avoid 
dividing peaks between multiple bins [194-197]. Since noise is biologically irrelevant and 
has been shown to bias PCA and PLS, noise regions should be removed prior to any 
multivariate statistical analysis [198, 199]. In addition to these spectral variations, the total 
signal intensity may vary across a set of NMR spectra due to differences in the number of 
cells, biofluid volume, or tissue size per sample. Thus, the absolute NMR peak intensities 
need to be normalized to a common reference or standard. Common normalization 
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techniques include normalization to the total signal intensity, probabilistic quotient 
normalization, contrast normalization and quantile normalization [200]. Normalization may 
also rely on an internal TMSP-d4 standard or an external standard such as cell culture 
optical density or protein content [201, 202]. Finally, the data needs to be scaled in order to 
avoid the multivariate analysis from only focusing on changes to the most intense peaks 
[201]. Effectively, the disparity in intensities and variances between peaks needs to be 
minimized in order for changes in low or high concentrated metabolite to make equal 
contributions to the PCA, PLS, or OPLS model. A range of scaling methods have been 
described [201] that emphasize different features of the spectrum and have different 
advantages and disadvantages.
The primary application of 1D 1H NMR spectra is to characterize the global metabolomic 
changes. The large number of metabolites and the limited chemical shift dispersion in a 1D 
spectrum lead to severe peak overlap that makes metabolite identification very challenging. 
As a result, alternative methods have been developed or implemented to simplify metabolite 
identification. These approaches include 1D NMR methods such as selective total 
correlation spectroscopy (TOCSY) [203, 204], and statistical methods such as statistical 
total correlation spectroscopy (STOCSY) [205] and ratio analysis nuclear magnetic 
resonance spectroscopy (RANSY) [206]. In addition, two-dimensional (2D) NMR 
experiments routinely employed to characterize natural products (1H-13C heteronuclear 
single quantum correlation, HSQC; 2D 1H-1H TOCSY) are also used for metabolite 
identification [158]. The 2D NMR experiments significantly reduce peak overlap by 
dispersing the chemical shift information into two-dimensions. Importantly, these 
experiments also improve the accuracy of peak identification by providing chemical shift 
information for correlated nuclei, such as 13C-1H and 1H-1H pairs in the 2D 1H-13C HSQC 
and 2D 1H-1H TOCSY experiments, respectively. Unfortunately, these NMR experiments 
are significantly more time-consuming than the simpler 1D experiment, requiring upwards 
of hours to complete. Also, 13C-based NMR experiments require even longer acquisition 
times or the incorporation of 13C labeled metabolites because of the low natural abundance 
(1.1%) and sensitivity of 13C. However, the 2D 1H-13C HSQC experiment has a unique 
advantage when cells can be cultured with a 13C labeled carbon source. Only a subset of the 
metabolome is highlighted and the 13C label can be traced as it flows through specific 
metabolic pathways. Of course, this requires a judicious selection of the 13C-probe to 
monitor the appropriate metabolic pathways.
2.6. Metabolomics applied to PD
2.6.1. PD biomarker identification using the metabolome
2.6.1.1 Targeted metabolomics studies: An exciting potential of metabolomics is the 
identification of biomarkers to diagnose PD, to monitor disease progression, and to evaluate 
a patient's response to treatment. Thus, a primary goal of metabolomics is to identify or 
“discover” the specific metabolites significantly perturbed in response to a disease state. 
What are the metabolites that are biologically relevant or correlated with PD? Conversely, a 
traditional targeted approach follows changes to a few select metabolites based on prior 
knowledge or hypothesis. Correspondingly, targeted analysis has identified metabolite 
variations in CSF, blood and urine samples obtained from PD patients and animal models 
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[207-211]. For example, Ahmed et al. [207] evaluated 22 targeted metabolites in plasma 
samples obtained from 37 healthy controls and 43 drug-naïve PD patients by using 1D 1H 
NMR and multivariate analysis. The 22 metabolites were selected based on prior 
connections with PD as cited in the literature. Metabolites were identified using a 
combination of 2D COSY and TOCSY NMR experiments, and an NMR reference library 
for 292 metabolites to assign the chemical shifts observed in the 1D 1H NMR spectra.
These metabolites were shown to incur statistically significant changes (P < 0.05; ANOVA) 
in PD plasma samples. Of the 22 targeted metabolites, 17 metabolites were decreased and 5 
were elevated in PD patients (Figure 5a). The heat map depicts metabolite concentration 
differences between healthy controls and PD patients. The relative metabolite concentrations 
are indicated by a color gradient. Red indicates an increase in the average metabolite 
concentration and green a decrease. The metabolites with a decrease in concentration are 
suberate, methylmalonate, galactitol, citrate, malate, succinate, glycerol, isocitrate, 
ethanolamine, ascorbate, threonate, gluconate, acetate, trimethylamine, glutarate, 
methylamine and glucolate, while the five elevated metabolites are pyruvate, sorbitol, 
myoinositol, ethymalonate and propylene glycol. It is important to note that a typical heat 
map would normally contain all of the individual replicates instead of the group-wise 
average presented by Ahmed et al. By including all replicates, it would be possible to assess 
the within group variability and, critically, determine if all the patients from the diseased and 
normal groups cluster together. This would provide an important quality check to further 
substantiate the relevance of each of the 22 targeted metabolites to PD. Simply, is the 
metabolite uniformly increased or decreased across the 43 PD patients and 37 healthy 
controls? The data was also used to train an artificial neural network (ANN) for PD 
diagnosis. The resulting ANN had a classification accuracy of 97.14% and a 100% 
specificity. Importantly, this classification accuracy was computed on held-out samples.
A PLS 2D scores plot generated from the NMR data identified a clear separation between 
PD patients and healthy controls (Figure 5b). Unfortunately, no statistical validation of the 
class separation in the PLS scores plot was provided. Again, PLS is a supervised method, is 
inherently biased and will always show a separation in the scores plot regardless of the 
existence of any true separation between the classes [178]. The separation in the PLS scores 
plot is determined by the manually defined class designation, where the follow-up validation 
step determines if this observed separation is statistically significant. Thus, the PLS result is 
very difficult to interpret. Instead, PCA would have been a more appropriate choice to 
provide a direct assessment of the significance of the class separation between PD patients 
and healthy controls. PCA is unsupervised, does not use class designations, and, as a result, 
is inherently unbiased. Nevertheless, PLS is useful for identifying the spectral features and, 
correspondingly, the metabolites that primarily contribute to the class separation in the 
scores plot. Of course, any subsequent analysis is dependent on the reliability of the original 
PLS model.
Myoinositol, glucitol, citrate, acetate, and pyruvate were identified as the key contributors to 
the class separation in the PLS scores plot and, thus, may serve as potential biomarkers if the 
PLS model is valid. The observed increase in myoinositol may be indicative of a decrease in 
sciatic motor-nerve conduction velocity. It is well-established that diabetic neuropathy in 
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both humans and animal models is observed through the slowing of nerve conduction [212], 
which is also correlated with an increase in plasma and urine myoinositol levels [213, 214], 
and a corresponding decrease of myoinositol in nerve cells [215]. As a result, a complex 
metabolic mechanism has been proposed that correlates this myoinositol defect with the 
slowing of nerve conduction in diabetes [215]. This pathogenic scheme includes the polyols 
pathway, Na+-K+-ATPase activity, protein kinase C activity and phosphoinositide 
metabolism. The increase in sorbitol in PD may result from oxidative stress. The change in 
both myoinositol and sorbitol also implies a dysfunction of the polyols metabolic pathway 
and, correspondingly, a malfunctioning mitochondrion. Pyruvate (increased) is an end 
product of glycolysis that then enters the tricarboxylic acid cycle (TCA cycle) as acetyl-coA, 
where the other TCA metabolites citrate, acetate, succinate and malate were decreased. 
These results suggest an abnormal activity in pyruvate dehydrogenase. Interestingly, a 
differential down-regulation in the PDHB gene that has pyruvate dehydrogenase activity is 
also consistent with the observed increase in pyruvate levels and a decrease in TCA 
metabolites in the plasma of PD patients [207]. Correspondingly, Ahmed et al. suggests that 
pyruvate plasma levels may be a diagnostic for PD. Of course, given pyruvate's central role 
in metabolism, it is highly unlikely that pyruvate will be a unique biomarker for PD since 
pyruvate will probably be affected by other diseases besides PD.
Unfortunately, multiple discrepancies have been reported in the literature for metabolites 
associated with PD (Table 1). Importantly, the magnitude of these discrepancies can be 
misleading since different sets of metabolites were targeted by different studies. For 
instance, none of the 22 metabolites described above (Figure 5) and the focus of the study by 
Ahmed et al. [194] were selected by the four other studies summarized in Table 1. 
Nevertheless, there are still differences in the identity of the metabolites; and the magnitude 
and direction of the concentration changes do differ between some of these existing studies. 
These contradictory results may be attributed to the different analytical techniques (LCECA, 
GC-MS) employed by these studies. This also leads to variations in sample preparation 
procedures, storage conditions, and sample sizes. Moreover, differences in the selection of 
study participants (random, age/sex matched, family member inclusion), variations in the 
disease phenotype (various PD genetic variants), disease progression, and disease treatment 
all potentially play a major role in the inconsistency of the identified potential biomarkers. 
Furthermore, as discussed previously, there are multiple factors contributing to the etiology 
of PD that includes age, exposure to pesticides and herbicides, and head trauma. A different 
set of metabolite biomarkers are potentially associated with each etiology. Finally, a variety 
of other factors such as diet, life-style, and comorbidity could create a complex background 
and mask metabolites associated with PD. Correspondingly, the design of the study and how 
these various factors are controlled or normalized may explain or contribute to the observed 
discrepancies (Table 2).
As an illustration, Tohgi et al. [208] reported a dramatic reduction in the concentration of 
aspartate, glutamate and δ-aminobutyric acid (GABA), and a modest, but significant 
reduction of glycine in the CSF from PD patients compared to healthy controls. However, 
Jiménez-Jiménez et al. [209] demonstrated that PD patients had similar CSF glutamate, 
glutamine, asparagine and glycine levels. CSF GABA levels in PD patients were still higher 
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than in healthy controls. Alternatively, plasma glutamine, asparagine, and glycine levels 
were higher, aspartate levels were lower, and glutamate and GABA levels were similar in 
PD patients relative to healthy controls. The results of Jiménez-Jiménez et al. also showed 
an increase in CSF glycine levels and an increase in plasma aspartate and GABA levels after 
levodopa therapy; an increase in plasma glutamine levels after treatment with a dopamine 
agonist; and a decrease in CSF and plasma glutamate levels, and plasma aspartate levels 
after deprenyl treatment. Alternatively, Mally et al. [210] observed a highly significant 
decrease in glutamate levels, a slight decrease in alanine, lysine and isoleucine levels, and a 
significant increase in glutamine level in the CSF from PD patients. Mally et al. did observe 
a decrease in glutamate similar to Tohgi et al. Fewer metabolite changes were observed in 
the serum of PD patients, which included a decrease in the levels of arginine and 
methionine, and an increase in the levels of valine. Finally, Weisskopf et al. [211] observed 
a reduction in uric acid (a natural antioxidant) levels in the plasma of PD patients.
Importantly, the study design varied significantly across these four projects (Table 2). There 
was a large variation in the treatments received by PD patients. Tohgi et al. included PD 
patients that were either receiving L-DOPA or no treatment at all. Conversely, Jiménez-
Jiménez et al. included PD patients receiving a variety of treatments, Mally et al. only 
included PD patients that were not receiving a treatment and Weisskopf et al. did not report 
patient treatments. Similarly, there was a ten year range in the average age of the PD 
patients between the studies, a high of 71.5 for the Weisskopf et al. study and a low of 59.8 
for the Tohgi et al. study. A similar variation was observed in the number of participants. 
Weisskopf et al. included 84 PD patients and 165 healthy controls, while the Mally et al. 
study only included 10 PD patients and 10 healthy controls. The Weisskopf et al. study used 
matched case controls, where the others used random controls. Critically, the PD patients 
were not further classified into PD stage or phenotype in any of these studies.
2.6.1.2 Untargeted metabolomics studies: Untargeted metabolomics has been recently 
applied to PD in order to identify disease biomarkers and for the investigation of drug 
metabolites resulting from PD treatment [216-220]. Bogdanov et al. [216] identified 
approximately 2000 metabolites in plasma samples obtained from 25 healthy controls and 
66 PD patients by using high performance liquid chromatography coupled with 
electrochemical coulometric array detection (LCECA). A resulting PLS 2D scores plot 
showed a statistically significantly separation (P < 0.01 by permutation test) for the 
metabolic profiles between healthy and PD patients. The main metabolites contributing to 
the observed PLS separation was an increase in 8-hydroxydeoxyguanosine (8-OHdG) and a 
decrease in uric acid and glutathione in the plasma of PD patients. Johansen et al. [217] 
applied a similar metabolomics strategy, LCECA combined with multivariate data analysis, 
to assess changes in plasma samples obtained from PD patients with the G2019S LRRK2 
(PARK8) mutation. The study also enrolled PD patients without any known mutation 
(idiopathic) and asymptomatic family members of those PD patients with or without the 
G2019S LRRK2 (PARK8) mutations. Again, 2D scores plots from PLS depicted an obvious 
visual separation (no statistical significance was presented) between the metabolic profiles 
for LRRK2 (PARK8) mutation patients, idiopathic patients and control subjects. The 
metabolomic analysis also indicated an aberration in the purine pathway in PD. Michell et 
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al. [218] investigated the metabolic profiles of serum and urine samples from 23 female 
patients with Parkinson's disease (PD) and 23 age and sex-matched controls using GC-MS, 
PCA and PLS. Contrary to the Bogdanov et al. [216] and Johansen et al. [217] studies, PCA 
or PLS (P = 0.67; χ2 test) did not yield a separation between healthy and PD patients using 
serum samples. Furthermore, PCA did not yield a separation between healthy and PD 
patients using urine samples, but interestingly, PLS did (P < 0.01; χ2 test). Importantly, the 
separation in the 3D PLS scores plot could not be attributed to any particular metabolite. 
This suggests that only a subtle difference exists in the metabolome between healthy and PD 
patients. These contradictory results could be attributed to the different experimental 
protocols and variations in the study designs (Table 2). Ahmed et al. included PD patients 
from three stages of PD, while Johansen et al. recruited idiopathic PD patients or patients 
with the LRRK2 (PARK8) PD variant. Again, there were variations in the number of 
participants (23 to 66 PD patients, 15 to 37 controls), average age range of the participants 
(55.7 to 68.6), and PD treatments.
2.6.2. PD pathogenesis investigation using metabolomics—Metabolomics is also 
an invaluable systems biology tool and an important approach for studying the underlying 
mechanisms associated with PD. Abnormal choline metabolism and mitochondrial electron 
transport system (ETS) dysfunction have been closely associated with central nervous 
system diseases like PD, but the relationship between ETS and choline metabolism is not 
well-understood. Towards this end, Baykal et al. investigated the relationship between 
functionally impaired ETS and choline metabolism using NMR metabolomics [221]. Human 
SH-SY5Y neuroblastoma cells were treated with a set of ETS inhibitors, where each 
compound selectively inhibited one of the five (I through V) ETS complexes. The extracted 
cellular metabolome were analyzed by 1D 1H NMR and PCA. Metabolites of choline and 
phosphorylcholine were further quantified by matrix-assisted laser desorption/ionization 
mass spectrometer (MALDI-TOF MS). Each ETS complex inhibitor resulted in a separate 
cluster in the PCA 2D scores plot consistent with a distinct perturbation of the cellular 
metabolome. Thus, the inhibition of each ETS complex leads to a specific mitochondrial 
dysfunction, and a distinct phenotype. Nevertheless, all the ETS complex inhibitors resulted 
in a significant increase in choline and associated metabolites. This is consistent with the 
observation that choline is elevated in CNS diseases [222, 223]. The increase in choline may 
occur because the ETS complex inhibitors may also target choline metabolic enzymes as 
evident by an observed increase in the induction of choline kinase by all of the inhibitors.
Gao et al. [220] used 1D 1H-NMR spectroscopy and PLS to detect metabolic changes in the 
striatum of 6-OHDA-induced Parkinson's rat. The right striatum of Sprague–Dawley rats 
were injected with 1.5 μg/μL of 6-OHDA. After the rats were sacrificed, specimens of both 
right (6-OHDA dosed) and left (control) striatum were dissected, followed by extraction of 
the metabolome for analysis by NMR. As expected, the resulting PLS 2D scores plot 
indicated a clear separation between the control and 6-OHDA treated groups. Unfortunately, 
the PLS model was not statistically validated making it difficult to interpret the reliability of 
the results. The corresponding PLS loading plot indicated that glutamate and glutamine were 
among the major contributors to the class separation. A statistically significant (p < 0.05) 
increase in glutamate and δ-aminobutyric acid (GABA), and a decrease in glutamine was 
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also observed for the 6-OHDA treated striatum based on a comparison between normalized 
NMR integrals. These results suggest a likely shift in the steady-state equilibrium of the 
Gln-Glu cycle between astrocytes and neurons. A change in the Gln-Glu cycle would disrupt 
the balance between excitatory and inhibitory brain processes that would potentially lead to 
long-term abnormalities in glutamatergic and GABAergic activities. 6-OHDA induced 
perturbations in other cerebral metabolites (alanine, lactate, N-acetyl aspartate and taurine) 
that also suggest the possible involvement of energy metabolism and the TCA cycle in the 
pathogenesis of PD.
2.6.2. PD drug discovery using metabolomics—In addition to biomarker discovery 
and mechanistic studies, Sun et al. [219] demonstrated the use of metabolomics to 
investigate drug metabolism in PD. During the evaluation of a potential new drug, it is 
critical to ascertain both the drug's efficacy and toxicity. Tolcapone, a catechol-O-methyl 
transferase inhibitor for PD treatment, was used to dose Sprague-Dawley rats. Urine samples 
were collected over a 28 day period to identify the metabolite profile. UPLC/MS, MS/MS 
(MS2) combined with multivariate statistical analysis was used to investigate the impact of 
tolcapone on the urine metabolome. A total of 15 different metabolites of tolcapone were 
identified using both positive and negative modes of LC/MS and MS2. While two of the 
observed metabolites, could be oxidatively bioactivated to induce liver toxicity, these 
reactive species were not observed and histopathology analysis indicated no significant 
changes. The PCA 2D score plots show complete separation between the control group, and 
the day 1 and day 28 dosed groups (Figure 6). Importantly, tolcapone and the metabolites of 
tolcapone were the primary contributors to this class separation. Also, there was a 
significantly larger separation between the control group and the day 28 dosed group. This is 
consistent with the accumulation of tolcapone and its metabolites from multiple doses.
3. Conclusions
3.1. Merits of metabolomics for PD research
Parkinson's disease is a CNS disorder with a high heterogeneity in clinical symptoms, with 
multiple etiological factors, and numerous, not well-understood pathological mechanisms. 
Metabolomics offers a unique opportunity to study this complex disease from a systems 
biological perspective. Changes in the metabolome are correlated with phenotypes, and are a 
direct result of alterations in protein and enzyme activities. Thus, metabolomics may provide 
critical information on cellular processes, molecular interactions and metabolic pathways 
associated with PD. Correspondingly, the electron transport system, choline metabolism, the 
Glu-Gln cycle, energy metabolism and TCA cycle have been implicated in PD from NMR 
metabolomics studies discussed in this review. Other highlighted metabolomics studies 
demonstrate the great potential of using NMR metabolomics to identify novel biomarkers 
for diagnosing PD, for personalized medicine, and for aiding in drug discovery and 
development. But, there are also clear challenges with the application of metabolomics to 
study PD.
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3.2 Limitations of metabolomics
The metabolomics studies presented in this review yielded contradictory results in the 
identification of metabolite biomarkers for PD. This unfortunate outcome is likely due to a 
combination of experimental errors, the use of different analytical techniques, the use of 
different targeted metabolites, the heterogeneity of PD, and different study designs. The 
appeal of metabolomics is the simplicity of the methodology, but it is also easy to obtain 
erroneous results. Simply, the metabolome is sensitive to any variation in experimental 
conditions.
The metabolome is a heterogeneous mixture of compounds with a range of turn-over rates, 
stabilities, solubilities, and volatilities. Thus, improper sample handling and preparation 
procedures may perturb the composition of a biological sample. For example, removing an 
extraction solvent like methanol may also result in removing other volatile metabolites. 
Also, residual enzymatic activity would affect the concentrations of associated substrates, 
co-factors and products. A biological sample is nutrient-rich, so a loss of sterility would also 
result in a dramatic change in the sample composition. Concentrating or drying a biological 
sample may result in the precipitation of specific metabolites due to limited solubility or 
changes in ionic strength or pH. Similar effects may result from choice of buffer or pH. The 
solubility of a metabolite can also be negatively affected by the presence of other 
metabolites in the sample. How long the sample is kept at room temperature, how long the 
sample is stored before analysis, and how many freeze-thaw cycles a sample undergoes are 
all factors that can perturb the composition of a biological sample.
Different analytical techniques (NMR, MS, IR, LCECA, etc.) have different strengths and 
limitations, and hence, emphasize different regions of the metabolome. Thus, it is not 
surprising that the application of various analytical techniques may also result in different 
outcomes. NMR is relatively insensitive technique and will only detect the most abundant 
metabolites, so a change in a low concentration metabolite would be unobservable by NMR. 
In contrast, MS depends on compound ionization and volatility. A number of metabolites do 
not produce a detectable molecular ion [224]. Moreover, the heterogeneity and complexity 
of the metabolome may lead to additional ion suppression and further diminish the detection 
of weakly ionizable metabolites. In addition, the application of chromatography to separate 
the metabolome may change the relative concentrations of a select set of metabolites in the 
MS spectrum. Again, the diversity of the physiochemical properties of metabolites will 
inevitably lead to a range of compound recoveries from chromatography columns; and 
correspondingly, result in relative changes in metabolite concentrations.
An observed difference (or lack of a difference) in the metabolome of biofluids from healthy 
and PD patients depends both on the disease and patient demographics. A patient's lifestyle, 
medical history, disease progression, medical treatments, gender, age, race, diet, etc. are all 
likely to affect their metabolome and may obscure the expected similarities between PD 
patients or between healthy controls. For example, a difference in the metabolome would be 
expected between PD patients receiving or not receiving a drug treatment. In fact, this 
difference may mask any similarities in the metabolome due to the disease itself. Similar 
issues arise if the PD patients have a variety of disease etiology or are at different stages of 
disease progression. The situation becomes even more complex when participants vary in 
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sex, age, diet, lifestyle behavior, and comorbidity, to name just a few possibilities. Again, all 
these factors are likely to affect the metabolome and obscure any within group similarities. 
As a result, it becomes difficult to find a common difference in the metabolome between PD 
patients and healthy controls. In fact, any metabolite identified as a potential PD biomarker 
may simply be a result of a coincidence or from another prominent demographic besides PD. 
Thus, the inconsistency in the observed PD metabolite biomarkers (PCA, PLS, and OPLS) is 
not unexpected given the diversity in the patient demographics (Table 2).
3.3 Potential solutions and future directions
Validating and optimizing the experimental protocol is fundamental to a reliable 
metabolomics study [88, 133, 140-155, 161]. This is achieved by eliminating or minimizing 
all factors that cause undesirable changes in metabolite concentrations. In practice, this may 
be challenging, but general goals include minimizing the number of experimental steps and 
limiting sample handling, making the process as fast as possible, keeping the sample cold or 
frozen at all times, and analyzing the samples as soon as feasible.
The possibility that various analytical techniques may yield different outcomes for a 
metabolomics study can be turned into strength. As highlighted above, analytical techniques 
have different limitations and advantages, in essence, the techniques should be viewed as 
complementary to each other. Thus, a current trend in metabolomics is the integration of 
multiple techniques in a metabolomics study [122-124].
PD is a heterogeneous disease and the analysis of the metabolome to identify potential 
biomarkers requires a focused approach. Correctly addressing this challenge requires 
controlling or eliminating all patient variables besides the specific disease state. Ideally, all 
the PD patients should have the same etiology and stage of PD, and are not receiving any 
drug treatment. The participants should be the same age, sex, and equally healthy. Diet 
should be strictly controlled and alcohol consumption, smoking, and other medications 
should be eliminated. In effect, the only difference in the metabolome between the control 
and PD group should result from PD. Of course, this scenario could be very challenging to 
achieve in practice.
Also, observing a change in a metabolite between a control and PD group does not 
necessarily infer the discovery of a PD biomarker. The potential PD biomarkers need to be 
validated. One valuable approach is to simply repeat the study with a second group of 
participants and confirm the identification of the same set of metabolites. For the majority of 
the PD studies reported here, the number of participants in each class (healthy vs. PD) is too 
small (< 80) for statistical significance (α 0.05, power 90%), especially given the presence 
of other variables [225]. Also, a number of the models generated from supervised 
multivariate analysis were not validated [92, 179]. Similarly, the statistical significance of 
the defined group clusters in the PCA, PLS and OPLS scores plot are generally not 
evaluated [176, 226]. These are common occurrences in metabolomics studies, and are not 
unique to the PD field. Thus, the metabolomics community needs to adopt standard 
protocols for reporting the statistical validation of metabolomics data that also needs to be 
enforced by publishers [227]. The lack of validation in the PD studies reported herein does 
not necessarily negate the value of the individual outcomes, but it does raise a serious 
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concern especially given the observed inconsistencies between the various PD metabolomic 
studies. Additionally, the significance of a change in a specific metabolite and its 
relationship to PD needs to be statistically verified [227, 228]. If a set of metabolites are 
proposed as a potential diagnostic test for PD, the statistical significance of the metabolite 
set also needs to be adjusted for multiple comparisons using the Benjamini-Hochberg, 
Bonferroni, Holm, or other similar methods [229, 230]. The observed metabolite biomarkers 
may not be unique to PD and may be associated with other CNS diseases, an immune 
response or some other comorbidity. Thus, the inclusion of multiple control groups, 
emphasizing a global analysis of the metabolome, increasing the number of participants, 
validating the multivariate models, and repeat studies using a second study group are all 
critical to a successful outcome from a PD metabolomics study. Metabolomics is still a 
relatively new field of study and, as a result, experimental protocols are still being 
developed and optimized. Correspondingly, the application and impact of metabolomics on 
PD has been limited to date. Nevertheless, as the methodology continues to evolve and 
improve, metabolomics has the potential of making significant contributions to PD research.
Acknowledgments
This work was supported in part by funds from the Nebraska Research Council and the National Institutes of Health 
(P20 RR017675 and P30 GM103335). The research was performed in facilities renovated with support from the 
National Institutes of Health (NIH, RR015468-01).
References
1. Thomas B, Beal M. Parkinson's disease. Human molecular genetics. 2007; 16(Spec No. 2):94.
2. Cookson M. The biochemistry of Parkinson's disease. Annual review of biochemistry. 2005; 74:29–
52.
3. Moore D, West A, Dawson V, Dawson T. Molecular pathophysiology of Parkinson's disease. 
Annual review of neuroscience. 2005; 28:57–87.
4. Dorsey E, Constantinescu R, Thompson J, Biglan K, Holloway R, Kieburtz K, Marshall F, Ravina 
B, Schifitto G, Siderowf A, Tanner C. Projected number of people with Parkinson disease in the 
most populous nations, 2005 through 2030. Neurology. 2007; 68(5):384–386. [PubMed: 17082464] 
5. Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson's disease: 
evidence from studies of non-human primates. Nat Rev Neurosci. 2011; 12(6):359–366. [PubMed: 
21587290] 
6. Wright WA, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in 
Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 
2010; 34(3):143–151. [PubMed: 20090375] 
7. Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early 
treatment. Am J Manag Care. 2010; 16 Suppl Implications:S87–93. [PubMed: 20297871] 
8. Nagy C, Bernard M, Hodes R. National Institute on Aging at middle age--its past, present, and 
future. Journal of the American Geriatrics Society. 2012; 60(6):1165–1169. [PubMed: 22646926] 
9. Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol. 2012; 8:435–442. [PubMed: 
22777251] 
10. Fearnley J, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 
1991; 114(Pt 5):2283–2301. [PubMed: 1933245] 
11. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and 
the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical 
correlations. Journal of the neurological sciences. 1973; 20(4):415–455. [PubMed: 4272516] 
12. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet neurology. 2006; 
5(1):75–86.
Lei and Powers Page 18
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
13. Agarwal P, Stoessl A. Biomarkers for trials of neuroprotection in Parkinson's disease. Movement 
disorders : official journal of the Movement Disorder Society. 2013; 28(1):71–85. [PubMed: 
22927101] 
14. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of parkinson disease: molecules to 
medicine. J Clin Invest. 2006; 116(7):1744–1754. [PubMed: 16823471] 
15. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci. 1994; 
15:264–270. [PubMed: 7940991] 
16. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004; 363(9423):1783–1793. 
[PubMed: 15172778] 
17. Dunnett SB, Björklund A. Prospects for new restorative and neuroprotective treatments in 
Parkinson's disease. Nature. 1999; 399:A32–A39. [PubMed: 10392578] 
18. Mercuri NB, Bernardi G. The ‘magic’ of L-dopa: why is it the gold standard Parkinson's disease 
therapy? Trends Pharmacol Sci. 2005; 26(7):341–344. [PubMed: 15936832] 
19. Shults C. Lewy bodies. Proceedings of the National Academy of Sciences of the United States of 
America. 2006; 103(6):1661–1668. [PubMed: 16449387] 
20. Okazaki H, Lipkin L, Aronson S. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) 
associated with progressive dementia and quadriparesis in flexion. Journal of neuropathology and 
experimental neurology. 1961; 20:237–244. [PubMed: 13730588] 
21. Iwatsubo T. Pathological biochemistry of alpha-synucleinopathy. Neuropathology : official journal 
of the Japanese Society of Neuropathology. 2007; 27(5):474–478. [PubMed: 18018483] 
22. Goedert M, Spillantini MG, Del TK, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 
2013; 9(1):13–24. [PubMed: 23183883] 
23. Breydo L, Wu JW, Uversky VN. α-Synuclein misfolding and Parkinson's disease. Biochim 
Biophys Acta, Mol Basis Dis. 2012; 1822(2):261–285.
24. Korlipara LVP, Schapira AHV. Parkinson's disease. Int Rev Neurobiol. 2002; 53:283–314. 
[PubMed: 12512344] 
25. Pimentel C, Batista-Nascimento L, Rodrigues-Pousada C, Menezes RA. Oxidative stress in 
Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae. Oxid 
Med Cell Longevity. 2012; 2012 Epub 132146. 
26. Nakamura T, Lipton SA. Redox modulation by S-nitrosylation contributes to protein misfolding, 
mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death 
Differ. 2011; 18(9):1478–1486. [PubMed: 21597461] 
27. Ross OA, Farrer MJ. Parkinson disease-moving beyond association. Nat Rev Neurol. 2010; 6(6):
305–307. [PubMed: 20531431] 
28. Factor SA, Sanchez-Ramos J, Weiner WJ. Trauma as an etiology of parkinsonism: a historical 
review of the concept. Mov Disord. 1988; 3(1):30–36. [PubMed: 3050470] 
29. Kamel F, Hoppin JA. Association of pesticide exposure with neurologic dysfunction and disease. 
Environ Health Perspect. 2004; 112(9):950–958. [PubMed: 15198914] 
30. Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J 
Neurol Sci. 2007; 262(1-2):37–44. [PubMed: 17673256] 
31. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological 
perspective. Trends Pharmacol Sci. 2008; 29(6):322–329. [PubMed: 18453001] 
32. Droździk M, Bialecka M, Myśliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in 
the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and 
genetic factors in Parkinson's disease. Pharmacogenetics. 2003; 13(5):259–263. [PubMed: 
12724617] 
33. Tsuboi Y. Environmental-genetic interactions in the pathogenesis of Parkinson's disease. 
Experimental neurobiology. 2012; 21(3):123–128. [PubMed: 23055790] 
34. Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, 
Boyer R, Stenroos E, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson W, 
Lazzarini A, Duvoisin R, Di Iorio G, Golbe L, Nussbaum R. Mutation in the alpha-synuclein gene 
identified in families with Parkinson's disease. Science (New York, N Y). 1997; 276(5321):2045–
2047.
Lei and Powers Page 19
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
35. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti 
R, Calne D, Stoessl A, Pfeiffer R, Patenge N, Carbajal I, Vieregge P, Asmus F, Müller-Myhsok B, 
Dickson D, Meitinger T, Strom T, Wszolek Z, Gasser T. Mutations in LRRK2 cause autosomal-
dominant parkinsonism with pleomorphic pathology. Neuron. 2004; 44(4):601–607. [PubMed: 
15541309] 
36. Sriram SR, Li X, Ko HS, Chung KKK, Wong E, Lim KL, Dawson VL, Dawson TM. Familial-
associated mutations differentially disrupt the solubility, localization, binding and ubiquitination 
properties of parkin. Hum Mol Genet. 2005; 14(17):2571–2586. [PubMed: 16049031] 
37. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, 
Bras J, Brice A, Chen CM, Clark L, Condroyer C, De Marco E, Dürr A, Eblan M, Fahn S, Farrer 
M, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario 
C, Kropp P, Lang A, Lee-Chen GJ, Lesage S, Marder K, Mata I, Mirelman A, Mitsui J, Mizuta I, 
Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira L, Quattrone A, Rogaeva E, Rolfs A, 
Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, 
Tan EK, Tayebi N, Toda T, Troiano A, Tsuji S, Wittstock M, Wolfsberg T, Wu YR, Zabetian C, 
Zhao Y, Ziegler S. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. 
The New England journal of medicine. 2009; 361(17):1651–1661. [PubMed: 19846850] 
38. Whitworth AJ, Pallanck LJ. The PINK1/Parkin pathway: A mitochondrial quality control system? 
J Bioenerg Biomembr. 2009; 41(6):499–503. [PubMed: 19967438] 
39. Cookson MR. Pathways to parkinsonism. Neuron. 2003; 37(1):7–10. [PubMed: 12526767] 
40. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harbor Perspect Med. 
2012; 2(1):a008888/008881–a008888/008815.
41. DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E. The association between 
mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord. 2009; 
24(11):1571–1578. [PubMed: 19425057] 
42. Janda E, Isidoro C, Carresi C, Mollace V. Defective Autophagy in Parkinson's Disease: Role of 
Oxidative Stress. Mol Neurobiol. 2012; 46(3):639–661. [PubMed: 22899187] 
43. Castro IP, Martins LM, Loh SHY. Mitochondrial Quality Control and Parkinson's Disease: A 
Pathway Unfolds. Mol Neurobiol. 2011; 43(2):80–86. [PubMed: 21120708] 
44. Lehmann S, Martins LM. Insights into mitochondrial quality control pathways and Parkinson's 
disease. J Mol Med (Heidelberg, Ger). 2013; 91(6):665–671.
45. Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell 
Biochem. 1997; 174(1&2):305–319. [PubMed: 9309704] 
46. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 
2000; 10(9):369–377. [PubMed: 10932094] 
47. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants 
in normal physiological functions and human disease. Int J Biochem Cell Biol. 2006; 39(1):44–84. 
[PubMed: 16978905] 
48. Cotman, CW.; Peterson, C. Aging in the nervous system. In: Fleischer, S.; Packer, L., editors. 
Basic Neurochemistry. 4th. Academic Press; New York: 1989. p. 382-389.
49. Paulson OB. Blood-brain barrier, brain metabolism and cerebral blood flow. Eur 
Neuropsychopharmacol. 2002; 12(6):495–501. [PubMed: 12468012] 
50. Mayhew JE. Neuroscience: a measured look at neuronal oxygen consumption. Science. 2003; 
299:1023–1024. [PubMed: 12586929] 
51. Ikonomidou C, Kaindl AM. Neuronal Death and Oxidative Stress in the Developing Brain. 
Antioxid Redox Signaling. 2011; 14(8):1535–1550.
52. Takahashi S, Takahashi I, Sato H, Kubota Y, Yoshida S, Muramatsu Y. Age-related changes in the 
concentrations of major and trace elements in the brain of rats and mice. Biological trace element 
research. 2001; 80(2):145–158. [PubMed: 11437180] 
53. Cadenas E. Biochemistry of oxygen toxicity. Annual review of biochemistry. 1989; 58:79–110.
54. Skulachev V. Mitochondrial physiology and pathology; concepts of programmed death of 
organelles, cells and organisms. Molecular aspects of medicine. 1999; 20(3):139–184. [PubMed: 
10626278] 
Lei and Powers Page 20
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
55. Büeler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's 
disease. Exp Neurol. 2009; 218(2):235–246. [PubMed: 19303005] 
56. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson's disease: 
molecular mechanisms and pathophysiological consequences. Embo J. 2012; 31(14):3038–3062. 
[PubMed: 22735187] 
57. Wang X, Michaelis Elias K. Selective neuronal vulnerability to oxidative stress in the brain. Front 
Aging Neurosci. 2010; 2:12. [PubMed: 20552050] 
58. Lau YS, Meredith GE. From drugs of abuse to Parkinsonism: The MPTP mouse model of 
Parkinson's disease. Methods Mol Med. 2003; 79:103–116. [PubMed: 12506692] 
59. Saporito MS, Heikkila RE, Youngster SK, Nicklas WJ, Geller HM. Dopaminergic neurotoxicity of 
1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake 
system and inhibition of mitochondrial respiration. J Pharmacol Exp Ther. 1992; 260(3):1400–
1409. [PubMed: 1312170] 
60. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic 
systemic pesticide exposure reproduces features of Parkinson's disease. Nature neuroscience. 
2000; 3(12):1301–1306.
61. Fornai F, Schlüter O, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, 
Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof T. Parkinson-like syndrome 
induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and 
alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of 
America. 2005; 102(9):3413–3418. [PubMed: 15716361] 
62. Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF. The role of mitochondrial 
dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell 
Biochem. 1997; 174(1-2):193–197. [PubMed: 9309687] 
63. Sherer T, Betarbet R, Testa C, Seo B, Richardson J, Kim J, Miller G, Yagi T, Matsuno-Yagi A, 
Greenamyre J. Mechanism of toxicity in rotenone models of Parkinson's disease. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 2003; 23(34):10756–10764. 
[PubMed: 14645467] 
64. Schapira A, Cooper J, Dexter D, Jenner P, Clark J, Marsden C. Mitochondrial complex I 
deficiency in Parkinson's disease. Lancet. 1989; 1(8649):1269. [PubMed: 2566813] 
65. Choi WS, Kruse S, Palmiter R, Xia Z. Mitochondrial complex I inhibition is not required for 
dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proceedings of the National 
Academy of Sciences of the United States of America. 2008; 105(39):15136–15141. [PubMed: 
18812510] 
66. Dawson TM. New animal models for Parkinson's disease. Cell. 2000; 101:115–118. [PubMed: 
10786830] 
67. Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role 
of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004; 318(1):225–241. 
[PubMed: 15258850] 
68. Emborg ME. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J 
Neurosci Methods. 2004; 139(2):121–143. [PubMed: 15488225] 
69. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. 
European journal of pharmacology. 1968; 5(1):107–110. [PubMed: 5718510] 
70. Beal M. Experimental models of Parkinson's disease. Nature reviews Neuroscience. 2001; 2(5):
325–334.
71. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003; 39(6):889–
909. [PubMed: 12971891] 
72. Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of alpha-synuclein fibril 
formation: a possible factor in Parkinson's disease. FEBS letters. 2001; 500(3):105–108. [PubMed: 
11445065] 
73. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. 
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-
synuclein metabolism and oxidative damage. The Journal of neuroscience : the official journal of 
the Society for Neuroscience. 2002; 22(16):7006–7015. [PubMed: 12177198] 
Lei and Powers Page 21
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
74. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible 
rotenone model of Parkinson's disease. Neurobiology of disease. 2009; 34(2):279–290. [PubMed: 
19385059] 
75. Thomas B, Mandir AS, West N, Liu Y, Andrabi SA, Stirling W, Dawson VL, Dawson TM, Lee 
MK. Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human 
α-synuclein and associated with increased β-synuclein and Akt activation. PloS One. 2011; 
6(1):e16706. [PubMed: 21304957] 
76. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000; 404(6776):
394–398. [PubMed: 10746727] 
77. Wang D, Tang B, Zhao G, Pan Q, Xia K, Bodmer R, Zhang Z. Dispensable role of Drosophila 
ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Molecular 
neurodegeneration. 2008; 3:3. [PubMed: 18257932] 
78. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, 
Przedborski S, Beal M, Burke R, Li C. Mutant LRRK2(R1441G) BAC transgenic mice 
recapitulate cardinal features of Parkinson's disease. Nature neuroscience. 2009; 12(7):826–828.
79. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a 
component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate 
excitotoxicity. Neuron. 2003; 37(5):735–749. [PubMed: 12628165] 
80. Moore DJ, Dawson TM. Value of genetic models in understanding the cause and mechanisms of 
Parkinson's disease. Current neurology and neuroscience reports. 2008; 8(4):288–296. [PubMed: 
18590612] 
81. Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited 
by endotoxin. Free radical research. 2001; 35(6):885–893. [PubMed: 11811539] 
82. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing 
enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. 
Cell. 2002; 111(2):209–218. [PubMed: 12408865] 
83. Gebregiworgis T, Powers R. Application of NMR Metabolomics to Search for Human Disease 
Biomarkers. Comb Chem High Throughput Screening. 2012; 15(8):595–610.
84. Zhang B, Powers R. Using NMR-based metabolomics to study the regulation of biofilm formation. 
Future Med Chem. 2012; 4(10):1273–1306. [PubMed: 22800371] 
85. Powers R. NMR metabolomics and drug discovery. Magnetic Resonance in Chemistry. 2009; 
47:S2–S11. [PubMed: 19504464] 
86. Fiehn O. Metabolomics - the link between genotypes and phenotypes. Plant Mol Biol. 2002; 
48(1-2):155–171. [PubMed: 11860207] 
87. Nicholson JK, Lindon JC, Holmes E. “Metabonomics”: understanding the metabolic responses of 
living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR 
spectroscopic data. Xenobiotica. 1999; 29(11):1181–1189. [PubMed: 10598751] 
88. Bando K, Kawahara R, Kunimatsu T, Sakai J, Kimura J, Funabashi H, Seki T, Bamba T, Fukusaki 
E. Influences of biofluid sample collection and handling procedures on GC-MS based 
metabolomic studies. J Biosci Bioeng. 2010; 110(4):491–499. [PubMed: 20547363] 
89. Lauridsen M, Hansen SH, Jaroszewski JW, Cornett C. Human Urine as Test Material in 1H NMR-
Based Metabonomics: Recommendations for Sample Preparation and Storage. Anal Chem. 2007; 
79(3):1181–1186. [PubMed: 17263352] 
90. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. HPLC-MS-based methods for 
the study of metabonomics. J Chromatogr, B: Anal Technol Biomed Life Sci. 2005; 817(1):67–76.
91. Ellis DI, Goodacre R. Metabolic fingerprinting in disease diagnosis: biomedical applications of 
infrared and Raman spectroscopy. Analyst. 2006; 131:875–885. [PubMed: 17028718] 
92. Worley B, Powers R. Multivariate Analysis in Metabolomics. Current Metabolomics. 2013; 1(1):
92–107.
93. Weckwerth W. Metabolomics in systems biology. Annu Rev Plant Biol. 2003; 54:669–689. 
[PubMed: 14503007] 
94. Kell DB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol. 
2004; 7(3):296–307. [PubMed: 15196499] 
Lei and Powers Page 22
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
95. Schmidt C. Metabolomics takes its place as latest up-and-coming “omic” science. Journal of the 
National Cancer Institute. 2004; 96(10):732–734. [PubMed: 15150298] 
96. Tian J, Shi C, Gao P, Yuan K, Yang D, Lu X, Xu G. Phenotype differentiation of three E. coli 
strains by GC-FID and GC-MS based metabolomics. J Chromatogr, B: Anal Technol Biomed Life 
Sci. 2008; 871(2):220–226.
97. t'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, Dujardin JC, Breitling R, Watson DG, 
Coombs GH, Decuypere S. Metabolomics to unveil and understand phenotypic diversity between 
pathogen populations. PLoS Neglected Trop Dis. 2010; 4(11):e904.
98. Cavill R, Kamburov A, Ellis JK, Athersuch TJ, Blagrove MSC, Herwig R, Ebbels TMD, Keun 
HC. Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for 
metabolism in the chemosensitivity of tumour cells. PLoS Comput Biol. 2011; 7(3):e1001113. 
[PubMed: 21483477] 
99. Halouska S, Fenton RJ, Barletta RG, Powers R. Predicting the in Vivo Mechanism of Action for 
Drug Leads Using NMR Metabolomics. ACS Chem Biol. 2012; 7(1):166–171. [PubMed: 
22007661] 
100. Wei R. Metabolomics and its practical value in pharmaceutical industry. Curr Drug Metab. 2011; 
12(4):345–358. [PubMed: 21395528] 
101. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, Ampt K, Stingl C, Dane A, 
Muilwijk B, Luitwieler RL, Silievis SPAE, Hintzen RQ, Bischoff R, Wijmenga SS, Hankemeier 
T, van, G AJ, Luider TM. Quantitative proteomics and metabolomics analysis of normal human 
cerebrospinal fluid samples. Mol Cell Proteomics. 2010; 9(9):2063–2075. [PubMed: 20811074] 
102. Le GG, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, Colquhoun IJ, Kemsley EK, 
Narbad A. Metabolomics of Fecal Extracts Detects Altered Metabolic Activity of Gut Microbiota 
in Ulcerative Colitis and Irritable Bowel Syndrome. J Proteome Res. 2011; 10(9):4208–4218. 
[PubMed: 21761941] 
103. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass 
spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific 
profiles. Metabolomics. 2010; 6(1):78–95. [PubMed: 20300169] 
104. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller 
G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL. Detection of epithelial 
ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer. 2005; 113(5):782–788. 
[PubMed: 15499633] 
105. Gavaghan CL, Holmes E, Lenz E, Wilson ID, Nicholson JK. An NMR-based metabonomic 
approach to investigate the biochemical consequences of genetic strain differences: application to 
the C57BL10J and Alpk:ApfCD mouse. FEBS Lett. 2000; 484(3):169–174. [PubMed: 
11078872] 
106. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker 
and pathway discovery. J Am Coll Cardiol. 2008; 52(2):117–123. [PubMed: 18598890] 
107. Griffin JL, Nicholls AW. Metabolomics as a functional genomic tool for understanding lipid 
dysfunction in diabetes, obesity and related disorders. Pharmacogenomics. 2006; 7(7):1095–
1107. [PubMed: 17054419] 
108. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical Applications of Metabolomics in Oncology: A 
Review. Clin Cancer Res. 2009; 15(2):431–440. [PubMed: 19147747] 
109. Barba I, Fernandez-Montesinos R, Garcia-Dorado D, Pozo D. Alzheimer's disease beyond the 
genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J Cell Mol 
Med. 2008; 12(5A):1477–1485. [PubMed: 18554316] 
110. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell 
DB, Barker RA, Grainger DJ, Rubinsztein DC. Huntington disease patients and transgenic mice 
have similar pro-catabolic serum metabolite profiles. Brain. 2006; 129(Pt 4):877–886. [PubMed: 
16464959] 
111. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros 
P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH Jr, 
Kaddurah-Daouk R. Metabolomic analysis and signatures in motor neuron disease. 
Metabolomics. 2005; 1(2):101–108. [PubMed: 18820733] 
Lei and Powers Page 23
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
112. Tsang TM, Huang JTJ, Holmes E, Bahn S. Metabolic Profiling of Plasma from Discordant 
Schizophrenia Twins: Correlation between Lipid Signals and Global Functioning in Female 
Schizophrenia Patients. J Proteome Res. 2006; 5(4):756–760. [PubMed: 16602681] 
113. Paige LA, Mitchell MW, Krishnan KRR, Kaddurah-Daouk R, Steffens DC. A preliminary 
metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry. 2007; 
22(5):418–423. [PubMed: 17048218] 
114. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, 
Wenning GK. Movement Disorders Society Scientific Issues Committee report: SIC Task Force 
appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003; 18(5):467–
486. [PubMed: 12722160] 
115. Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol. 2002; 9 
Suppl 3:23–30. [PubMed: 12464118] 
116. Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using ‘omics’ to define pathogenesis and 
biomarkers of Parkinson's disease. Expert review of neurotherapeutics. 2010; 10(6):925–942. 
[PubMed: 20518609] 
117. Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand 
metabolic networks. Comparative and functional genomics. 2001; 2(3):155–168. [PubMed: 
18628911] 
118. Förster J, Famili I, Fu P, Palsson B, Nielsen J. Genome-scale reconstruction of the 
Saccharomyces cerevisiae metabolic network. Genome research. 2003; 13(2):244–253. 
[PubMed: 12566402] 
119. Shellie RA, Welthagen W, Zrostliková J, Spranger J, Ristow M, Fiehn O, Zimmermann R. 
Statistical methods for comparing comprehensive two-dimensional gas chromatography-time-of-
flight mass spectrometry results: metabolomic analysis of mouse tissue extracts. Journal of 
chromatography A. 2005; 1086(1-2):83–90. [PubMed: 16130658] 
120. Tolstikov VV, Lommen A, Nakanishi K, Tanaka N, Fiehn O. Monolithic silica-based capillary 
reversed-phase liquid chromatography/electrospray mass spectrometry for plant metabolomics. 
Analytical chemistry. 2003; 75(23):6737–6740. [PubMed: 14640754] 
121. Shi H, Vigneau-Callahan KE, Matson W, Kristal BS. Attention to relative response across 
sequential electrodes improves quantitation of coulometric array. Analytical biochemistry. 2002; 
302(2):239–245. [PubMed: 11878803] 
122. Agnolet S, Jaroszewski JW, Verpoorte R, Staerk D. 1H NMR-based metabolomics combined 
with HPLC-PDA-MS-SPE-NMR for investigation of standardized Ginkgo biloba preparations. 
Metabolomics. 2010; 6(2):292–302. [PubMed: 20526353] 
123. Sun B, Li L, Wu S, Zhang Q, Li H, Chen H, Li F, Dong F, Yan X. Metabolomic analysis of 
biofluids from rats treated with Aconitum alkaloids using nuclear magnetic resonance and gas 
chromatography/time-of-flight mass spectrometry. Anal Biochem. 2009; 395(2):125–133. 
[PubMed: 19683504] 
124. Crockford DJ, Holmes E, Lindon JC, Plumb RS, Zirah S, Bruce SJ, Rainville P, Stumpf CL, 
Nicholson JK. Statistical Heterospectroscopy, an Approach to the Integrated Analysis of NMR 
and UPLC-MS Data Sets: Application in Metabonomic Toxicology Studies. Anal Chem. 2006; 
78(2):363–371. [PubMed: 16408915] 
125. Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, 
Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der 
Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H, Akksilp R, Sitti W, Wattanaamornkiet 
W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, 
Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, 
Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, 
Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Min S, Degtyareva I, Nemtsova ES, 
Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee 
HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, 
Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P. Prevalence of and risk factors for 
resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: 
a prospective cohort study. Lancet. 2012; 380(9851):1406–1417. [PubMed: 22938757] 
Lei and Powers Page 24
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
126. Cao M, Zhao L, Chen H, Xue W, Lin D. NMR-based metabolomic analysis of human bladder 
cancer. Analytical sciences : the international journal of the Japan Society for Analytical 
Chemistry. 2012; 28(5):451–456. [PubMed: 22687923] 
127. Duarte IF, Gil A. Metabolic signatures of cancer unveiled by NMR spectroscopy of human 
biofluids. Progress in nuclear magnetic resonance spectroscopy. 2012; 62:51–74. [PubMed: 
22364616] 
128. Wijeyesekera A, Selman C, Barton RH, Holmes E, Nicholson JK, Withers DJ. Metabotyping of 
long-lived mice using 1H NMR spectroscopy. Journal of proteome research. 2012; 11(4):2224–
2235. [PubMed: 22225495] 
129. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, 
McKilligin E, Mosedale DE, Grainger D. Rapid and noninvasive diagnosis of the presence and 
severity of coronary heart disease using 1H-NMR-based metabonomics. Nature medicine. 2002; 
8(12):1439–1444.
130. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, Zhang CM, Wang Y, Liu P, Tu BB, Zhang X, 
Qiao J. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: 
plasma metabolomics analysis. BMC medicine. 2012; 10(1):153. [PubMed: 23198915] 
131. Vinaixa M, Rodriguez MA, Samino S, Díaz M, Beltran A, Mallol R, Bladé C, Ibañez L, Correig 
X, Yanes O. Metabolomics reveals reduction of metabolic oxidation in women with polycystic 
ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PloS One. 2011; 
6(12):e29052. [PubMed: 22194988] 
132. Maher AD, Lindon JC, Nicholson JK. 1H NMR-based metabonomics for investigating diabetes. 
Future medicinal chemistry. 2009; 1(4):737–747. [PubMed: 21426036] 
133. Beckonert O, Keun HC, Ebbels TMD, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic 
profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, 
serum and tissue extracts. Nat Protoc. 2007; 2(11):2692–2703. [PubMed: 18007604] 
134. Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic 
approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 
2005; 18(3):143–162. [PubMed: 15627238] 
135. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and 
their applications in physiological monitoring, drug safety assessment and disease diagnosis. 
Biomarkers. 2004; 9(1):1–31. [PubMed: 15204308] 
136. Lindon JC, Nicholson JK, Holmes E, Everett JR. Metabonomics: metabolic processes studied by 
NMR spectroscopy of biofluids. Concepts Magn Reson. 2000; 12(5):289–320.
137. Moestue S, Sitter B, Bathen TF, Tessem MBB, Gribbestad IS. HR MAS MR spectroscopy in 
metabolic characterization of cancer. Current topics in medicinal chemistry. 2011; 11(1):2–26. 
[PubMed: 20809888] 
138. Peskind E, Nordberg A, Darreh-Shori T, Soininen H. Safety of lumbar puncture procedures in 
patients with Alzheimer's disease. Curr Alzheimer Res. 2009; 6:290–292. [PubMed: 19519311] 
139. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, 
Raskind MA, Galasko D. Safety and acceptability of the research lumbar puncture. Alzheimer 
Dis Assoc Disord. 2005; 19:220–225. [PubMed: 16327349] 
140. Beloueche-Babari M, Jackson LE, Al-Saffar NMS, Eccles SA, Raynaud FI, Workman P, Leach 
MO, Ronen SM. Identification of magnetic resonance detectable metabolic changes associated 
with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular 
cancer therapeutics. 2006; 5(1):187–196. [PubMed: 16432178] 
141. Lane AN, Fan TWM. Quantification and identification of isotopomer distributions of metabolites 
in crude cell extracts using 1 H TOCSY. Metabolomics. 2007; 3(2):79–86.
142. Lin CY, Wu H, Tjeerdema RS, Viant MR. Evaluation of metabolite extraction strategies from 
tissue samples using NMR metabolomics. Metabolomics. 2007; 3(1):55–67.
143. León Z, García-Cañaveras JC, Donato MT, Lahoz A. Mammalian cell metabolomics: 
experimental design and sample preparation. Electrophoresis. 2013 accepted, ePub. 
144. Sellick CA, Hansen R, Maqsood AR, Dunn WB, Stephens GM, Goodacre R, Dickson AJ. 
Effective Quenching Processes for Physiologically Valid Metabolite Profiling of Suspension 
Cultured Mammalian Cells. Anal Chem (Washington, DC, U S). 2009; 81(1):174–183.
Lei and Powers Page 25
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
145. Sellick CA, Hansen R, Stephens GM, Goodacre R, Dickson AJ. Metabolite extraction from 
suspension-cultured mammalian cells for global metabolite profiling. Nat Protoc. 2011; 6(8):
1241–1249. [PubMed: 21799492] 
146. Van Gulik WM, Canelas AB, Taymaz-Nikerel H, Douma RD, de Jonge LP, Heijnen JJ. Fast 
sampling of the cellular metabolome. Methods Mol Biol (N Y, NY, U S). 2012; 881(Microbial 
Systems Biology):279–306.
147. Villas-Bôas SG, Hoejer-Pedersen J, Aakesson M, Smedsgaard J, Nielsen J. Global metabolite 
analysis of yeast: Evaluation of sample preparation methods. Yeast. 2005; 22(14):1155–1169. 
[PubMed: 16240456] 
148. Sheedy JR, Ebeling PR, Gooley PR, McConville MJ. A sample preparation protocol for 1H 
nuclear magnetic resonance studies of water-soluble metabolites in blood and urine. Anal 
Biochem. 2010; 398(2):263–265. [PubMed: 19941831] 
149. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, 
Knowles JD, Halsall A, Haselden JN, Nicholls AW, Wilson ID, Kell DB, Goodacre R. 
Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography 
and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011; 6(7):1060–1083. 
[PubMed: 21720319] 
150. Danielsson APH, Moritz T, Mulder H, Spégel P. Development and optimization of a 
metabolomic method for analysis of adherent cell cultures. Anal Biochem. 2010; 404(1):30–39. 
[PubMed: 20417172] 
151. Dettmer K, Nürnberger N, Kaspar H, Gruber MA, Almstetter MF, Oefner PJ. Metabolite 
extraction from adherently growing mammalian cells for metabolomics studies: optimization of 
harvesting and extraction protocols. Anal Bioanal Chem. 2011; 399(3):1127–1139. [PubMed: 
21125262] 
152. Martineau E, Tea I, Loaëc G, Giraudeau P, Akoka S. Strategy for choosing extraction procedures 
for NMR-based metabolomic analysis of mammalian cells. Anal Bioanal Chem. 2011; 401(7):
2133–2142. [PubMed: 21837464] 
153. J A, Trygg J, Gullberg J, Johansson AI, Jonsson P, Antti H, Marklund SL, Moritz T. Extraction 
and GC/MS Analysis of the Human Blood Plasma Metabolome. Anal Chem. 2005; 77(24):8086–
8094. [PubMed: 16351159] 
154. Maher AD, Zirah SFM, Holmes E, Nicholson JK. Experimental and Analytical Variation in 
Human Urine in 1H NMR Spectroscopy-Based Metabolic Phenotyping Studies. Anal Chem 
(Washington, DC, U S). 2007; 79(14):5204–5211.
155. Zhang Q, Wang G, Du Y, Zhu L, J A. GC/MS analysis of the rat urine for metabonomic research. 
J Chromatogr, B: Anal Technol Biomed Life Sci. 2007; 854(1-2):20–25.
156. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, Cudkowicz M, Glass 
J, Jahn O, Lehnert S, Malaspina A, Parnetti L, Petzold A, Shaw P, Sherman A, Steinacker P, 
Sussmuth S, Teunissen C, Tumani H, Wuolikainen A, Ludolph A. Roadmap and standard 
operating procedures for biobanking and discovery of neurochemical markers in ALS. 
Amyotroph Lateral Scler. 2012; 13(1):1–10. [PubMed: 22214350] 
157. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJA, 
Schepens M, Bouwman F, Twaalfhoven HAM, Blom HJ, Jakobs C, Dijkstra CD. Combination of 
CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009; 72(15):1322–
1329. [PubMed: 19365053] 
158. Zhang B, Halouska S, Schiaffo C, Sadykov M, Somerville G, Powers R. NMR analysis of a stress 
response metabolic signaling network. Journal of proteome research. 2011; 10(8):3743–3754. 
[PubMed: 21692534] 
159. Gebregiworgis T, Massilamany C, Gangaplara A, Thulasingam S, Kolli V, Werth MT, Dodds 
ED, Steffen D, Reddy J, Powers R. The Potential of Urinary Metabolites for Diagnosing Multiple 
Sclerosis. ACS Chem Biol. 2013; 8(4):684690.
160. Worley B, Halouska S, Powers R. Utilities for Quantifying Separation in PCA/PLSA-DA Scores. 
Anal Biochem. 2013; 433(2):102–104. [PubMed: 23079505] 
Lei and Powers Page 26
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
161. Álvarez-Sánchez B, Priego-Capote F, Luque de Castro MD. Metabolomics analysis I. Selection 
of biological samples and practical aspects preceding sample preparation. TrAC, Trends Anal 
Chem. 2010; 29(2):111–119.
162. Saude EJ, Sykes BD. Urine stability for metabolomic studies: effects of preparation and storage. 
Metabolomics. 2007; 3(1):19–27.
163. Teahan O, Gamble S, Holmes E, Waxman J, Nicholson JK, Bevan C, Keun HC. Impact of 
Analytical Bias in Metabonomic Studies of Human Blood Serum and Plasma. Anal Chem. 2006; 
78(13):4307–4318. [PubMed: 16808437] 
164. Quincy T, Wenlin H, Timothy WC, Drew RE, Chalet T. A direct cell quenching method for cell-
culture based metabolomics. Metabolomics. 2009; 5(2):199–208.
165. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-Based Metabolic Profiling and 
Metabonomic Approaches to Problems in Molecular Toxicology. Chem Res Toxicol. 2008; 
21(1):9–27. [PubMed: 18171018] 
166. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of 
mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance 
spectroscopy. Chem Soc Rev. 2011; 40(1):387–426. [PubMed: 20717559] 
167. Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and 
tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol. 
2003; 7(5):648–654. [PubMed: 14580571] 
168. Reo NV. NMR-based metabolomics. Drug Chem Toxicol. 2002; 25(4):375–382. [PubMed: 
12378948] 
169. Serkova NJ, Niemann CU. Pattern recognition and biomarker validation using quantitative 1H-
NMR-based metabolomics. Expert Rev Mol Diagn. 2006; 6(5):717–731. [PubMed: 17009906] 
170. Wishart DS. Quantitative metabolomics using NMR. TrAC, Trends Anal Chem. 2008; 27(3):
228–237.
171. Mercier KA, Shortridge MD, Powers R. A multi-step NMR screen for the identification and 
evaluation of chemical leads for drug discovery. Comb Chem High Throughput Screening. 2009; 
12(3):285–295.
172. Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical 
magnetic resonance. Progress in Nuclear Magnetic Resonance Spectroscopy. 2001; 39(1):1–40.
173. Holmes E, Nicholson JK, Nicholls AW, Lindon JC, Connor SC, Polley S, Connelly J. The 
identification of novel biomarkers of renal toxicity using automatic data reduction techniques and 
PCA of proton NMR spectra of urine. Chemom Intell Lab Syst. 1998; 44(1-2):245–255.
174. Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant 
analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemom. 2007; 
20(8-10):341–351.
175. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom Intell 
Lab Syst. 2001; 58(2):109–130.
176. Worley B, Halouska S, Powers R. Utilities for quantifying separation in PCA/PLS-DA scores 
plots. Analytical biochemistry. 2013; 433(2):102–104. [PubMed: 23079505] 
177. Brown M, Dunn WB, Ellis DI, Goodacre R, Handl J, Knowles JD, O'Hagan S, Spasić I, Kell DB. 
A metabolome pipeline: from concept to data to knowledge. Metabolomics. 2005; 1(1):39–51.
178. Kjeldahl K, Bro R. Some common misunderstandings in chemometrics. J Chemom. 2010; 
24(7-8):558–564.
179. Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, van Velzen EJJ, van Duijnhoven 
JPM, van Dorsten FA. Assessment of PLSDA cross validation. Metabolomics. 2008; 4:81–89.
180. Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS models. J 
Chemom. 2008; 22(11-12):594–600.
181. Wiklund S, Johansson E, Sjoestroem L, Mellerowicz EJ, Edlund U, Shockcor JP, Gottfries J, 
Moritz T, Trygg J. Visualization of GC/TOF-MS-Based Metabolomics Data for Identification of 
Biochemically Interesting Compounds Using OPLS Class Models. Anal Chem. 2008; 80(1):115–
122. [PubMed: 18027910] 
Lei and Powers Page 27
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
182. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: 
acquiring and understanding global metabolite data. Trends Biotechnol. 2004; 22(5):245–252. 
[PubMed: 15109811] 
183. Wongravee K, Lloyd GR, Silwood CJ, Grootveld M, Brereton RG. Supervised Self Organizing 
Maps for Classification and Determination of Potentially Discriminatory Variables: Illustrated by 
Application to Nuclear Magnetic Resonance Metabolomic Profiling. Anal Chem (Washington, 
DC, U S). 2010; 82(2):628–638.
184. Simula O, Kangas J. Process monitoring and visualization using self-organizing maps. Comput-
Aided Chem Eng. 1995; 6(1):371–384.
185. Brereton, R. Chemometrics for Pattern Recognition. 1. John Wiley & Sons, Inc; 2009. p. 522
186. Xu Y, Zomer S, Brereton RG. Support vector machines: a recent method for classification in 
chemometrics. Crit Rev Anal Chem. 2006; 36(3-4):177–188.
187. Beckonert O, Bollard ME, Ebbels TMD, Keun HC, Antti H, Holmes E, Lindon JC, Nicholson JK. 
NMR-based metabonomic toxicity classification: hierarchical cluster analysis and k-nearest-
neighbour approaches. Anal Chim Acta. 2003; 490(1-2):3–15.
188. Zhou, W.; Seoung Bum, K. In: Werner, R., editor. Automatic Alignment of High-Resolution 
NMR Spectra Using a Bayesian Estimation Approach; 18th International Conference on Pattern 
Recognition, 2006. ICPR 2006; Hong Kong, China. Hong Kong, China: IEEE Computer Society; 
2006. p. 667-670.2006
189. Wu W, Daszykowski M, Walczak B, Sweatman BC, Connor SC, Haseldeo JN, Crowther DJ, Gill 
RW, Lutz MW. Peak alignment of urine NMR spectra using fuzzy warping. Journal of Chemical 
Information and Modeling. 2006; 46(2):863–875. [PubMed: 16563018] 
190. Vu TN, Valkenborg D, Smets K, Verwaest KA, Dommisse R, Lemière F, Verschoren A, 
Goethals B, Laukens K. An integrated workflow for robust alignment and simplified quantitative 
analysis of NMR spectrometry data. BMC Bioinformatics. 2011; 12:405. [PubMed: 22014236] 
191. Beneduci A, Chidichimo G, Dardo G, Pontoni G. Highly routinely reproducible alignment of H-1 
NMR spectral peaks of metabolites in huge sets of urines. Analytica Chimica Acta. 2011; 685(2):
186–195. [PubMed: 21168568] 
192. Forshed J, Idborg H, Jacobsson SP. Evaluation of different techniques for data fusion of LC/MS 
and H-1-NMR. Chemometrics and Intelligent Laboratory Systems. 2007; 85(1):102–109.
193. Veselkov KA, Lindon JC, Ebbels TMD, Crockford D, Volynkin VV, Holmes E, Davies DB, 
Nicholson JK. Recursive Segment-Wise Peak Alignment of Biological 1H NMR Spectra for 
Improved Metabolic Biomarker Recovery. Anal Chem. 2009; 81(1):56–66. [PubMed: 19049366] 
194. De Meyer T, Sinnaeve D, Van Gasse B, Tsiporkova E, Rietzschel ER, De Buyzere ML, Gillebert 
TC, Bekaert S, Martins JC, Van Criekinge W. NMR-Based Characterization of Metabolic 
Alterations in Hypertension Using an Adaptive, Intelligent Binning Algorithm. Anal Chem. 
2008; 80(10):3783–3790. [PubMed: 18419139] 
195. Anderson PE, Mahle DA, Doom TE, Reo NV, DelRaso NJ, Raymer ML. Dynamic adaptive 
binning: an improved quantification technique for NMR spectroscopic data. Metabolomics. 2011; 
7(2):179–190.
196. Davis RA, Charlton AJ, Godward J, Jones SA, Harrison M, Wilson JC. Adaptive binning: An 
improved binning method for metabolomics data using the undecimated wavelet transform. 
Chemom Intell Lab Syst. 2007; 85(1):144–154.
197. Anderson PE, Reo NV, DelRaso NJ, Doom TE, Raymer ML. Gaussian binning: a new kernel-
based method for processing NMR spectroscopic data for metabolomics. Metabolomics. 2008; 
4(3):261–272.
198. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). Journal of Chemometrics. 
2002; 16(3):119–128.
199. Halouska S, Powers R. Negative impact of noise on the principal component analysis of NMR 
data. Journal of Magnetic Resonance. 2006; 178(1):88–95. [PubMed: 16198132] 
200. Kohl SM, Klein MS, Hochrein J, Oefner PJ, Spang R, Gronwald W. State-of-the art data 
normalization methods improve NMR-based metabolomic analysis. Metabolomics. 2012; 
8(Suppl. 1):146–160. [PubMed: 22593726] 
Lei and Powers Page 28
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
201. Craig A, Cloareo O, Holmes E, Nicholson JK, Lindon JC. Scaling and normalization effects in 
NMR spectroscopic metabonomic data sets. Analytical Chemistry. 2006; 78(7):2262–2267. 
[PubMed: 16579606] 
202. Sysi-Aho M, Katajamaa M, Yetukuri L, Orešič M. Normalization method for metabolomics data 
using optimal selection of multiple internal standards. BMC Bioinformatics. 2007; 8:93. 
[PubMed: 17362505] 
203. Sandusky P, Raftery D. Use of semiselective TOCSY and the pearson correlation for the 
metabonomic analysis of biofluid mixtures: application to urine. Analytical chemistry. 2005; 
77(23):7717–7723. [PubMed: 16316181] 
204. Sandusky P, Raftery D. Use of selective TOCSY NMR experiments for quantifying minor 
components in complex mixtures: application to the metabonomics of amino acids in honey. 
Analytical chemistry. 2005; 77(8):2455–2463. [PubMed: 15828781] 
205. Cloarec O, Dumas MED, Craig A, Barton RH, Trygg J, Hudson J, Blancher C, Gauguier D, 
Lindon JC, Holmes EE, Nicholson J. Statistical total correlation spectroscopy: an exploratory 
approach for latent biomarker identification from metabolic 1H NMR data sets. Analytical 
chemistry. 2005; 77(5):1282–1289. [PubMed: 15732908] 
206. Wei S, Zhang J, Liu L, Ye T, Gowda G, Tayyari F, Raftery D. Ratio analysis nuclear magnetic 
resonance spectroscopy for selective metabolite identification in complex samples. Analytical 
chemistry. 2011; 83(20):7616–7623. [PubMed: 21894988] 
207. Ahmed S, Santosh W, Kumar S, Christlet HT. Metabolic profiling of Parkinson's disease: 
evidence of biomarker from gene expression analysis and rapid neural network detection. Journal 
of biomedical science. 2009; 16:63. [PubMed: 19594911] 
208. Tohgi H, Abe T, Hashiguchi K, Takahashi S, Nozaki Y, Kikuchi T. A significant reduction of 
putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and 
spinocerebellar degeneration. Neuroscience letters. 1991; 126(2):155–158. [PubMed: 1681472] 
209. Jiménez-Jiménez F, Molina J, Vargas C, Gómez P, Navarro J, Benito-León J, Ortí-Pareja M, 
Gasalla T, Cisneros E, Arenas J. Neurotransmitter amino acids in cerebrospinal fluid of patients 
with Parkinson's disease. Journal of the neurological sciences. 1996; 141(1-2):39–44. [PubMed: 
8880690] 
210. Mally J, Szalai G, Stone TW. Changes in the concentration of amino acids in serum and 
cerebrospinal fluid of patients with Parkinson's disease. Journal of the neurological sciences. 
1997; 151(2):159–162. [PubMed: 9349670] 
211. Weisskopf M, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of 
Parkinson's disease. American journal of epidemiology. 2007; 166(5):561–567. [PubMed: 
17584757] 
212. Greene DA. Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve. 
Drugs. 1986; 32 Suppl 2:6–14. [PubMed: 3024950] 
213. Clements RS Jr, DeJesus PV Jr, Winegrad AI. Raised plasma-myoinositol levels in uraemia and 
experimental neuropathy. Lancet. 1973; 1(7813):1137–1141. [PubMed: 4123536] 
214. Clements RS Jr, Reynertson R. Myoinositol metabolism in diabetes mellitus. Effect of insulin 
treatment. Diabetes. 1977; 26(3):215–221. [PubMed: 838172] 
215. Greene DA, Lattimer SA, Sima AAF. Are disturbances of sorbitol, phosphoinositide, and sodium-
potassium-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes. 1988; 
37(6):688–693. [PubMed: 2838351] 
216. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Beal MF. 
Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008; 131(Pt 
2):389–396. [PubMed: 18222993] 
217. Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF, Bogdanov M. 
Metabolomic profiling in LRRK2-related Parkinson's disease. PloS One. 2009; 4(10):e7551. 
[PubMed: 19847307] 
218. Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in 
Parkinson's disease. Metabolomics. 2008; 4(3):191–201.
Lei and Powers Page 29
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
219. Sun J, Von Tungeln LS, Hines W, Beger RD. Identification of metabolite profiles of the catechol-
O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. 
J Chromatogr, B: Anal Technol Biomed Life Sci. 2009; 877:2557–2565.
220. Gao HC, Zhu H, Song CY, Lin L, Xiang Y, Yan ZH, Bai GH, Ye FQ, Li XK. Metabolic Changes 
Detected by Ex Vivo High Resolution 1H NMR Spectroscopy in the Striatum of 6-OHDA-
Induced Parkinson's Rat. Mol Neurobiol. 2013; 47(1):123–130. [PubMed: 22936308] 
221. Baykal AT, Jain MR, Li H. Aberrant regulation of choline metabolism by mitochondrial electron 
transport system inhibition in neuroblastoma cells. Metabolomics. 2008; 4(4):347–356. 
[PubMed: 19774105] 
222. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism 
in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology. 1993; 43(12):
2689–2695. [PubMed: 8255479] 
223. Elble R, Giacobini E, Higgins C. Choline levels are increased in cerebrospinal fluid of Alzheimer 
patients. Neurobiol Aging. 1989; 10(1):45–50. [PubMed: 2755556] 
224. Copeland JC, Zehr LJ, Cerny RL, Powers R. The Applicability of Molecular Descriptors for 
Designing an Electrospray Ionization Mass Spectrometry Compatible Library for Drug 
Discovery. Combinatorial Chemistry & High Throughput Screening. 2012; 15(10):806–815. 
[PubMed: 22708878] 
225. Hulley, SB.; Cummings, SR.; Browner, WS.; Grady, DG.; Newman, TB. Designing Clinical 
Research An Epidemiologic Approach. 3rd. Lippincott Williams and Wilkins; Philadelphia: 
2007. p. 367
226. Werth MT, Halouska S, Shortridge MD, Zhang B, Powers R. Analysis of Metabolomic PCA Data 
using Tree Diagrams. Analytical Biochemistry. 2010; 399(1):56–63.
227. Goodacre R, Broadhurst D, Smilde AK, Kristal BS, Baker JD, Beger R, Bessant C, Connor S, 
Capuani G, Craig A, Ebbels T, Kell DB, Manetti C, Newton J, Paternostro G, Somorjai R, 
Sjostrom M, Trygg J, Wulfert F. Proposed minimum reporting standards for data analysis in 
metabolomics. Metabolomics. 2007; 3(4):231–241.
228. Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and 
related experiments. Metabolomics. 2006; 2(4):171–196.
229. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach 
to multiple hypothesis testing. J R Stat Soc B. 1995; 57(1):289–300.
230. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the 
Bonferroni vs Holm methods. Am J Public Health. 1996; 86(5):726–728. [PubMed: 8629727] 
231. Mollenhauer B, Forstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and 
parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int. 2010; 
107(39):684–691. [PubMed: 20963199] 
Lei and Powers Page 30
Curr Metabolomics. Author manuscript; available in PMC 2015 June 13.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
(a) Annual US incidence of Parkinson's disease as a function of the patient's age. The 
occurrence of PD below age 65 is rare [6]. (b) α-synuclein aggregates in the cortex of 
patients with Lewy body dementia can be shown in the shape of Lewy bodies by using 
conventional histological techniques; Bar=50 μm (HE, arrow, inset) (Reprinted with 
permission from reference [231], Copyright 2010 by Deutscher Ärzte-Verlag GmbH).
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Figure 2. 
Chemical structures of L-DOPA, a common treatment for Parkinson's disease, and toxins, 
herbicides and pesticides known to selectively destroy dopamine neurons and induce 
Parkinson's disease in animals.
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Figure 3. 
(a) Illustration of NMR-based metabolomics work flow with (b) select examples of 
representative data and results [99, 158-160].
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Figure 4. 
Illustration of the principal component analysis of NMR spectra.
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Figure 5. 
(a) Heat map differentiation of metabolite. Average metabolite variability of blood plasma 
between PD patients (n = 43) and healthy controls (n = 37) are shown. Cluster analyses of 
the 22 differentially altered metabolites are selected based on significance P value (P < 
0.05). The heat map depicts high (red) and low (green) relative levels of metabolite 
variation. (b) Partial least square discriminant analysis. PLS scores plot showing a 
significant separation between control subjects (n = 37) and unmedicated PD patients (n = 
43) using complete digital maps. The observations coded according to class membership: 
black square = controls; red square = PD patients. (Reprinted with permission from 
reference [207], Copyright 2009 by BioMed Central Ltd.)
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Figure 6. 
The scores plot (a) from PCA analysis of the positive UPLC/MS data and (b) for negative 
UPLC/MS data for animals after day 1 and day 28 post-dosing of vehicle only (control) and 
200mg/kg tolcapone administration. (Reprinted with permission from reference [219], 
Copyright 2009 by Elsevier).
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